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Obesity is a strong risk factor for developing type 2 diabetes and cardiovascular 
disease and has quickly reached epidemic proportions with few tangible and safe 
treatment options. While it is generally accepted that the primary cause of obesity 
is energy imbalance, i.e., more calories are consumed than are utilized, 
understanding how caloric balance is regulated has proven a challenge. 
Molecular processes and pathways that directly regulate energy metabolism 
represent promising targets for therapy. In particular, nitric oxide (NO) is 
emerging as a central regulator of energy metabolism and body composition. NO 
bioavailability is decreased in animal models of obesity and in obese and insulin 
resistant patients, and increasing NO output has remarkable effects on obesity 
and insulin resistance. Additionally, deletion of eNOS (the source of NO in the 
vasculature) is associated with adiposity, insulin resistance and impaired fatty 
acid oxidation. The role of eNOS in regulating metabolism, however, is not well 
understood. We propose that decreased vascular-derived NO bioavailability 
during nutrient excess is a critical development that leads to metabolic 











metabolic changes in adipose tissue including profound decreases in eNOS 
abundance. Overexpression of eNOS prevents obesity and its related metabolic 
alterations while causing significant changes in energy expenditure and systemic 
metabolism. Our findings reveal potent anti-obesogenic effects of NO and 
demonstrate a significant role for NO in regulating metabolism. 
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The Obesity Epidemic 
The recent increase in the prevalence of obesity is alarming.  The Centers 
for Disease Control and Prevention (CDC) estimate that from 1962 to 2010 
prevalence of obesity has increased from 13% to 36%.  In 2008, approximately 
1.5 billion adults aged 20 years or older were overweight, and 10% were obese 1; 
more recent data from the United States indicate that >33% of adults and 17% of 
children are obese 2. This has led to a dramatic increase in individuals with pre-
diabetes. For example, current estimates indicate that one-third of the population 
in the US meets the criteria for pre-diabetes 3, 4, and, in addition to type 2 
diabetes (T2D), obesity is closely associated with co-morbidities such as 
coronary artery disease, hypertension, atherosclerosis, stroke, and cancer 5. 
Hence, the current high prevalence of obesity is likely to have a considerable 
impact on worldwide health.  In the US, the economic burden of obesity is 
substantial and accounts for an estimated $147 billion per year 6. The problem 
has become so severe that, in 2013, the American Medical Association House of 
Delegates declared obesity a disease. 
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 The principal cause of obesity is energy imbalance: the calories consumed 
are greater than that utilized by bodily processes, e.g., breathing, digestion, 
thermogenesis and mechanical work 7. Indeed, the average consumption of 
calories in the US increased by >200 kcal/d per person from 1971-2000, which is 
partly attributable to the abundance of affordable, widely marketed, energy-dense 
foods 8-11. Nevertheless, evidence suggests that the balance between calorie 
intake and energy expenditure is complex and regulated by many factors.  
Exposure to increasingly obesogenic environments has been suggested to 
promote not only overeating, but inactivity as well. For example, the human 
environment is fraught with both chemical and structural “obesogens.”  These 
include but are not limited to: pollutants that promote adiposity and insulin 
resistance 12-21; lack of structural features of the built environment that promote 
an active lifestyle, such as easy access to parks, sidewalks, and bike paths 22-24; 
and the night/day cycles in the natural environment of the individual, which can 
be altered in those having certain occupations 25-27. Moreover, the genetic 
makeup of individuals shows strong associations with the predisposition to 
become obese 28-30.  
Many of these factors influence body composition in an indirect or distal manner, 
and thus could be considered “distal causes” of obesity (Fig. 1).  Interventions to 
mitigate the effects of these distal causes are exceedingly difficult to test and 
implement. For example, changing the structural environment would likely entail 
departing from particular types of communities or neighborhoods. Similarly, living 
under favorable day-night cycles is difficult for workers in some occupations, and  
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Figure 1. Distal and proximal causes of obesity.  Influencing factors distal to 
the disease, such as policy as well as structural and chemical “obesogens” of the 
built and social (cultural) environment, may contribute to the prevalence of 
obesity. Funding for obesity research, dietary guidelines, physical education 
policies, and sidewalk standards are examples of potential influences related to 
Policy, which is most distal to the actual disease. The Built environment, which 
comprises places created or modified by people—i.e., where individuals work, 
their transportation systems, and life outside their homes—is another cause 
distal to obesity. The Social or cultural environment includes those family or 
cultural influences that affect behavioral activity, occupation (which may involve 
shift work), and social and media norms, all of which could affect eating habits 
and physical activity.  Lastly, direct mechanisms that control hunger, satiety, 
energy expenditure, and nutrient absorption are Proximal causes of obesity.  
Commonly, these proximal causes are more tangible targets for anti-
obesity/diabetes therapies compared with distal causes.  
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changing genetic makeup is currently not an option. Even weight loss via caloric 
restriction faces difficulties, including an evolution-engendered guard against low 
fat mass 7, 31 and the propensity of the body to increase caloric efficiency during 
dieting 32, 33. The intransigency of these problems has led to a search for causes 
more proximal to obesity, which may be tangible targets for anti-obesity 
therapies.    
 
Obesity, Insulin Resistance and Type 2 Diabetes 
The World Health Organization (WHO) defines obesity as abnormal or 
excessive fat accumulation that may impair health and is characterized by a body 
mass index (BMI) equal to or greater than 30 kg/m2. Evidence from numerous 
studies has demonstrated that obesity and increased weight gain are strongly 
associated with an increased risk of T2D 34-36 and that intentional weight loss 
decreases that risk 37. T2D is characterized by chronic hyperglycemia with 
disturbances of carbohydrate, protein and fat metabolism resulting from defects 
in insulin secretion, action or both 38. While a causal link between obesity and 
diabetes remains to be fully clarified, their association is undeniable. 
Development of effective treatments, therefore, depends on greater 
understanding of the metabolic dysregulation that accompanies the onset of 
obesity and its progression to insulin resistance and diabetes.  
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Metabolic pathways known to regulate obesity  
Understanding the mechanisms that promote adiposity and insulin resistance 
are critical to stem the growing tide of metabolic disease.  In particular, the 
development of therapies for obesity and T2D requires a better understanding of 
the biochemical pathways that regulate metabolism and body composition. As a 
first principle, energy balance must be considered to understand how changes in 
body composition could occur. Any effective obesity treatment must decrease 
energy intake, increase energy expenditure or both. Systems that regulate 
energy balance include: 
1) Hunger and satiety: The central nervous system regulates caloric intake 
and the feeling of satisfaction or fullness after a meal, i.e., satiety. This 
regulation is dependent on neural and endocrine inputs that can be 
divided into short- and long-term control systems. Release of 
cholecystokinin (CCK) in combination with neural signaling in response to 
gut distension are potent signals of satiety and trigger an end to feeding 39. 
The adipose tissue-derived hormone, leptin, is crucial to integrate the 
melanocortin neuronal circuit of the hypothalamus with the energy stores 
of the body 39-41. In addition to leptin, neuropeptide Y (NPY) directly affects 
feeding behavior, metabolism and body composition 42, 43, and 
corticotropin-releasing hormone, growth-hormone-releasing hormone, 
galanin and ghrelin, some of which are expressed in both the stomach and 
the brain, function in hunger and satiety signaling 44. The 
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neurotransmitters norepinephrine, dopamine and serotonin are also 
important in central energy balance 39, 41 and inhibiting their reuptake by 
drugs such as sibutramine, has proven anti-obesogenic effects but leads 
to side effects such as increased blood pressure and heart rate 45. Other 
drugs that have been shown to be effective in decreasing energy intake by 
suppressing appetite 7, 46, 47.     
2) Nutrient absorption: Targeting nutrient absorption in the gut may be an 
effective obesity therapy. Signals from the gut released post-prandially are 
important not only in regulating food intake, but also in digestion and 
nutrient absorption. Ghrelin and CCK, as well as, peptide YY, glucagon-
like peptides 1 and 2, gastric inhibitory peptide and corticotropin-releasing 
factor function to regulate both signaling and digestion [39, 43, 44]. 
Inhibition of gastric and pancreatic lipases via orlistat treatment decreases 
triglyceride hydrolysis and is able to inhibit absorption of ingested fat by 
~30% and contributes to a caloric deficit of approximately 200 calories per 
day [45].  As with neurotransmitter reuptake inhibitors, orlistat promotes 
weight loss; however, because of side effects the drug is poorly tolerated 
by many patients [40].   
3) Energy expenditure: The largest contributor to obligatory energy 
expenditure is the basal metabolic rate (BMR), which is defined as the 
resting energy expenditure at thermoneutrality in the unfed state 48. BMR 
includes cellular turnover, repair and basic functions (e.g., maintenance of 
ion gradients, transmembrane metabolite transfer), basal synthetic 
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reactions (e.g., RNA, DNA and protein synthesis) and mitochondrial 
proton leak. It also includes obligatory thermogenesis (e.g., digestion and 
absorption) 48.  
Mitochondria are central to the regulation of energy expenditure, 
and targeting their activity has been a prospect for obesity therapies for 
decades. Perhaps most infamous is the work by Cutting and Tainter 49, 50, 
which showed that 2,4-dinitrophenol (DNP)—a compound found to be 
responsible for weight loss in workers of French munitions factories during 
World War I—could be used to increase the metabolic rate of patients.  
Although the use of DNP led to weight loss as well as improvements in 
glucose tolerance in some diabetic patients, results were largely 
disastrous: people were “literally cooked to death” due to overdose, as the 
systemic uncoupling of mitochondria by DNP resulted in overheating. 
Other side effects included rashes, cataracts, and agranulocytosis.  
Hence, although the drug was effective for weight loss, it was not deemed 
safe by the FDA and was withdrawn from the market in 1938 51.    
In recent years, a more in-depth understanding of how 
mitochondrial metabolism could be regulated has been sought.  Unlike 
rudimentary approaches using pharmacological mitochondrial uncouplers, 
which have systemic effects, targeting mitochondrial metabolism in 
specific tissues may prove more beneficial.  Therapies that mimic 
physiological anti-obesogenic effects are likely to prove most effective.  
Mitochondria in organs with high energetic need (e.g., the heart) are likely 
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to maintain relatively well-coupled mitochondria, while other organs such 
as adipose tissue could afford to be less economical.  Overexpression of 
uncoupling protein 1 (UCP1), which generates an increase in substrate 
utilization and electron transport chain activity, in adipose tissue 52 or 
skeletal muscle 53 can prevent diet-induced obesity in mice, suggesting 
that uncoupling of oxidative phosphorylation in these two organs is 
sufficient to regulate body composition. Interestingly, oxidative 
phosphorylation in skeletal muscle is less well-coupled in endurance 
athletes compared with sedentary subjects 54, and this appears to result in 
an increase in fatty acid oxidation and a decrease in oxidative stress.  
Furthermore, genes encoding fatty acid oxidation are increased in the 
skeletal muscle of athletes compared with sedentary subjects 55, 
suggesting a gene profile in athletes that favors fat oxidation rather than 
storage 56.  
Brown adipose tissue (BAT), which expresses relatively high levels 
of UCP1, is an exciting target for therapy. Despite the small amounts in 
humans, as little as 50 g of BAT has been estimated to be capable of 
utilizing up to 20% of basal caloric needs 57. Mice with genetically reduced 
BAT mass are prone to obesity 58. The recent discovery that adult humans 
maintain active depots of BAT 59, 60 in conjunction with the identification of 
UCP2 and UCP3 in the skeletal muscle and other tissues 61, 62 suggests 
that enhancement of mitochondrial activity may hold promise for 
combatting obesity.   
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Increasing energy expenditure by BAT activation is an anti-obesity 
strategy that has recently gained widespread attention and represents an 
intriguing new therapeutic approach. However, the finding that adipocytes in 
some white adipose tissue depots can be programmed to become similar to BAT 
has further invigorated research into understanding the role of adipose tissue in 
systemic metabolism.   
 
White adipose tissue is an important regulator of whole-body metabolism  
 White adipose tissue (WAT) is a complex, essential and highly active 
metabolic and endocrine organ 63. Its utility as the main storage depot for excess 
energy from dietary intake has long been recognized 64, but only recently has its 
importance beyond energy storage been fully appreciated. WAT not only 
responds to afferent signals from traditional hormone systems and the central 
nervous system but it also expresses and secretes factors with important 
endocrine functions including cellular signaling, energy metabolism and 
inflammatory processes 63, 65. This network of secreted adipokines signal 
changes in the adipose tissue energy status to other metabolic organs that 
control fuel consumption and redistribution 66. In this way, adipose tissue is a 
critical regulator of whole-body metabolic homeostasis. The contribution of 
adipose tissue to regulating circulating levels of free fatty acids (FFAs), glucose 
and insulin is of particular importance 65 and will be discussed in detail in the 
following sections.  
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WAT dysfunction in the progression of obesity and diabetes  
Chronic energy overload promotes systemic metabolic dysfunction, which 
appears to commence at the level of the adipose tissue. Though adipocytes have 
a large capacity to synthesize and store triglycerides (TGs) during feeding, after 
prolonged periods of nutrient excess their storage and endocrine functions 
become compromised 67, 68. Failure of WAT to store fat appropriately results in 
pathological adipocyte hypertrophy, hypoxia and secretion of macrophage 
chemoattractants, particularly monocyte chemoattractant protein-1 (MCP-1) 65, 69. 
Infiltrating macrophages secrete large amounts of tumor necrosis factor  (TNF) 
and other inflammatory cytokines thereby creating a chronic proinflammatory 
state in the WAT associated with impaired TG deposition and increased lipolysis 
65. The result is increased circulating TGs and FFAs which can be deposited in 
skeletal muscle, liver and β-cells of the pancreas 70, 71. Elevated FFAs and 
ectopic lipid deposition are associated with metabolic dysregulation in peripheral 
tissues of both humans and rodents 72-78. In the liver, infusion of FFAs increases 
glucose output and causes insulin resistance 79. Similarly, skeletal muscle insulin 
resistance has been shown to be associated with elevated circulating FFAs and 
intramyocellular triglyceride accumulation 80, 81. Increased hepatic glucose 
production and decreased glucose uptake by skeletal muscle (which accounts for 
approximately 80% of glucose disposal in the post-prandial state) contributes to 
elevated systemic glucose levels 66. In response, the pancreas releases more 
insulin and after prolonged periods of positive energy balance, this leads to 
  12  
 
hyperinsulinemia 82. Additionally, chronic exposure to elevated FFAs may result 
in β-cell dysfunction 82, 83 a key event in the development of frank T2D.  
 
Proper lipid partitioning is critical in metabolic disease 
A critical feature in this model of disease progression is the failure of the 
WAT to benignly accommodate excess lipid. When the WAT is unable to 
sequester fat, a malignant cascade of events ensues. Studies in rodent models 
underscore the importance of fat storage in the adipocyte. These studies show 
that increasing adipocyte cell number, and therefore overall adipose tissue mass, 
by overexpressing the adipokine adiponectin in severely obese ob/ob mice, 
decreased hepatic and muscle fat deposits and normalized metabolic parameters 
84. Therefore, by providing additional adipose depots for fat storage, fat “spillover” 
or ectopic deposition in peripheral tissues can be prevented and insulin 
resistance and diabetes averted. This is further supported by the observation that 
mice almost totally devoid of adipose tissue due to the expression of A-ZIP/F-1 
protein in adipocytes, are severely insulin resistant due to defects in insulin 
action, particularly insulin receptor substrate (IRS)-1/IRS-2–dependent activation 
of PI 3-kinase, in muscle and liver 85. These abnormalities were associated with a 
twofold increase in muscle and liver triglyceride content, and upon 
transplantation of fat tissue into these mice, triglyceride content in muscle and 
liver returned to normal, as did insulin signaling and action 85, 86. While intensively 
studied, the mechanism by which increased lipid in peripheral tissues disrupts 
insulin signaling, remains to be fully elucidated 87. What is clear, however, is that 
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proper partitioning of fat in the WAT rather than in peripheral tissues is crucial for 
preserving insulin sensitivity.  
 
WAT mitochondria as therapeutic targets in metabolic disease 
 While numerous studies have focused on modulating mitochondrial 
activity in skeletal muscle and liver to prevent lipid accumulation and maintain 
insulin sensitivity, only recently has significant attention been paid to metabolic 
intervention at the level of the adipose tissue. Despite adipocytes having a 
relatively low mitochondrial abundance, mitochondria are essential for many 
adipocyte functions. Previous work has demonstrated that mitochondria play an 
important role in the differentiation and the maturation of adipocytes, as 
evidenced by a synchronized initiation of adipogenesis and mitochondrial 
biogenesis 88 and the promotion of differentiation in response to enhanced 
mitochondrial metabolism, biogenesis and reactive oxygen species (ROS) 
production 89. Additionally, adipocyte mitochondria must generate sufficient ATP 
to support energy-consuming lipogenic processes, while still maintaining normal 
cellular activity 90. Further, to sustain lipogenesis, mitochondria provide key 
intermediates for the synthesis of TGs through the actions of pyruvate 
carboxylase 91. Reacting to cues from its nutritional and hormonal 
microenvironment, the adipocyte coordinates the appropriate mitochondrial 
response to either oxidize incoming FAs and carbohydrates through the 
tricarboxylic acid (TCA) cycle and the respiratory chain, or store them as TGs 91. 
In light of this, it has been proposed that ‘FFA recycling in the adipocyte’ (a TG-
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to-FA cycle) is a crucial sequence of events that determines systemic FFA 
concentrations 92. 
During obesity and nutrient excess, mitochondrial function in adipocytes is 
compromised. Levels of ATP decrease while there is increased accumulation of 
NADH 66, thereby shifting the adipocyte toward lipid storage accompanied by 
reduced mitochondrial biogenesis and increased ATP synthesis from glycolysis 
91. Prolonged exposure to nutrient overload only further induces these 
mitochondrial alterations and leads to yet more lipid accumulation. Studies in 
diabetic mice have shown a decrease in both the number and the function (both 
oxidative phosphorylation and β-oxidation) of mitochondria in WAT 93. Further, 
several genes involved in mitochondrial function and oxidative phosphorylation, 
as well as PPARα, ERRα, and PGC-1α were downregulated in WAT from high 
fat diet-induced obese and db/db mice 94, 95. Similar changes have been 
observed in the WAT of obese, insulin resistant and diabetic patients. In human 
WAT, mitochondrial abundance is decreased and genes crucial for mitochondrial 
function are downregulated 96 as well. Adipocytes isolated from these patients 
had decreased oxygen consumption rates and ATP production 91, 97. These 
findings suggest a clear association between the activity of the mitochondria in 
adipose tissue and the pathological remodeling of the tissue that accompanies 
obesity.  
Targeting the mitochondria of WAT to combat obesity has emerged as a 
promising new strategy and has been the subject of increasing scientific scrutiny. 
A general idea is to increase mitochondria in WAT, which could promote a higher 
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basal metabolic rate.  Several molecular targets have been identified, with PGC-
1 being of critical importance 98. PGC-1 is a known regulator of energy 
metabolism and of mitochondrial biogenesis 99 and may induce many of the 
characteristic brown fat traits in white adipocytes in vitro 98. Additionally, recent 
studies have identified secreted proteins that stimulate brown adipocyte 
thermogenesis and recruit brown (or beige) adipocytes to WAT 100. One such 
secreted protein is irisin—a skeletal muscle-derived myokine that enhances 
systemic energy expenditure and improves obesity and glucose homeostasis in 
mice—via a mechanism, which depends, at least in part, on PGC-1 101.   
Interestingly, treatment with the gaseous signaling molecule, nitric oxide 
(NO), can induce PGC-1-dependent mitochondrial biogenesis in both mouse 
white fat 3T3-L1 adipocytes and brown adipocytes 102, 103. Importantly, NO-
induced mitochondrial biogenesis leads to the formation of functionally active 
mitochondria capable of coupled respiration leading to the generation of ATP 
through oxidative phosphorylation 104. Furthermore, emerging evidence suggests 
that changes in vascular function could regulate metabolic homeostasis, and 
many studies have shown that NO may play a pivotal role in regulating systemic 
metabolism, body composition, and insulin sensitivity.  In the sections that follow, 
the potential role of NO in regulating metabolism, obesity and insulin resistance 
is discussed. 
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Nitric oxide – endogenous formation and  
general modes of biological action 
Nitric oxide and related nitrogen oxides have emerged as critical 
regulators of cell and tissue function 105.  The potency of NO was perhaps first 
realized when it was inhaled by Sir Humphrey Davy, who nearly died from the 
self-experiment, and after which he vowed to “never design again…so rash an 
experiment” 106.  Nearly two centuries later, identification of the cardiovascular 
processes controlled by NO led to the Nobel Prize in Physiology or Medicine in 
1998.  Nevertheless, the pleiotropy of NO continues to unfold, and we are only 
now beginning to appreciate the deeper aspects of its impact on metabolism.  
 
Generation of NO  
The most common route of NO production is through the action of the 
nitric oxide synthase (NOS) family of enzymes 105, 107. These enzymes catalyze 
NADPH- and O2-dependent oxidation of L-arginine to L-citrulline, producing NO 
in the process.  Such synthesis of NO depends on the availability of cofactors 
such as FAD, FMN, tetrahydrobiopterin (BH4), as well as the prosthetic group, 
heme 108.   
The three NOS isoforms generate NO at different rates 105. Endothelial 
NOS (eNOS) is localized to the vascular endothelium, but has also been found in 
neurons, epithelial cells and cardiomyocytes 109.  It produces relatively low 
quantities of NO, and its activity is controlled by Ca2+ and calmodulin, post-
translational modifications 110, 111, and physical forces such as shear stress 112, 
113.  Neuronal NOS (nNOS) is also a Ca2+/calmodulin-dependent isoform that is 
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activated by agonists of the N-methyl-D-aspartate (NMDA) receptor 113.  It is 
expressed in neurons, skeletal muscle, and epithelial cells. Lastly, inducible NOS 
(iNOS), which has the highest capacity to generate NO, is expressed in multiple 
cell types in response to inflammatory stimuli 113, 114.  The results of some studies 
also suggest the presence of a mitochondria-localized isoform, which could be 
important in regulating mitochondrial function 115, 116; however, the identity of this 
isoform remains to be fully established. In addition to post-translational 
modifications and substrate and cofactor availability, NOS activity is regulated by 
its localization within cells and by interactions with itself and other proteins 113. 
NO could also be produced endogenously from its more oxidized nitrogen 
oxide precursor, nitrite.  Reduction of nitrite to NO is increased under acidic and 
hypoxic conditions, with the reduction occurring enzymatically by heme proteins 
such as deoxyhemoglobin or deoxymyoglobin 117.  The therapeutic potential of 
dietary or pharmacological nitrite is supported by multiple studies describing 
improvements in reperfusion injury following myocardial infarction, in pulmonary 
hypertension, and injury after organ transplantation 118. 
 
Biochemical properties of NO  
NO is a free radical of rather limited biological reactivity. The endogenous 
half-life of NO is in the range of 2 ms to > 2 s and appears to depend primarily on 
the availability of metals and oxygen 119. NO reacts avidly with ferrous (Fe2+) iron 
and with other radical species and such reactions form the basis for nearly all of 
the biological effects of NO. The highest affinity interactions of NO are with 
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metalloproteins such as soluble guanylate cyclase (sGC), cytochrome c oxidase, 
and hemoglobin; NO reacts also with non-heme iron.  Reaction of NO with Fe2+ 
iron results in the formation of a coordinate bond, which is termed a nitrosyl 
adduct (i.e., nitrosylation). The presence of free radicals such as superoxide  
(O2˙-) 120-123 changes the fate of NO because once NO reacts with O2˙- it  forms 
peroxynitrite 120, 122, 123 and can no longer bind to ferrous heme 124. Peroxynitrite 
and other reactive species (e.g., NO2) derived from the reaction of NO with O2˙- 
are important in inflammatory responses 123 and can modulate cell signaling 125-
128, in part by promoting the oxidation and nitration of a broad range of 
biomolecules 105.  
The NO molecule can also react directly with O2, which itself is a free 
radical possessing two unpaired electrons in different π* antibonding orbitals 129.  
The reaction of NO with O2 commonly underlies mechanisms by which S-
nitrosation or S-oxidation of protein side chains occurs.  In addition, NO can react 
directly with thiyl radicals, forming a nitroso covalent bond between NO and the 
thiol (termed S-nitrosation or S-nitrosylation). Cysteinyl residues of glutathione 
and proteins are among the most recognized and studied targets of NO and its 
oxidized species [(such as N2O3; collectively called reactive nitrogen species 
(RNS)]; reaction of RNS with thiols results in the formation of S-nitrosothiols, S-
glutathiolated species, and oxidized cysteinyl residues 130.  Such modifications 
can lead to transient changes in enzyme activity, providing redox switches that 
can be modulated by addition or removal of the modifications 131.  
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General physiological roles of NO 
NO has multiple biological actions and this versatile molecule can regulate 
physiology acutely or lead to long-term changes in cell function. The pleiotropic 
roles of NO include the regulation of long-term synaptic transmission, learning, 
memory, platelet aggregation, leukocyte-endothelial interactions, immune 
function, and angiogenesis and arteriogenesis (for review, see 132).  However, 
NO is most well known as a potent regulator of blood flow and was originally 
termed endothelial-derived relaxing factor (EDRF). The story unfolded from 
Furchgott and Zawadzki’s initial discovery that endothelial cells control 
acetylcholine-induced relaxation of smooth muscle 133. A few years later, NO was 
identified as the key endothelium-derived molecule promoting vasodilation: NO 
synthesized by NOS in the endothelium diffuses into the vessel wall where it 
activates sGC in vascular smooth muscle. This leads to an increase in cyclic 
GMP (cGMP) levels in the tissue and elicits vessel relaxation 134-140.  However, it 
readily became apparent that different isoforms of NOS have different 
physiological roles.  For example, eNOS and nNOS were found to have distinct 
roles in regulating microvascular tone 141; nNOS activity in the medulla and 
hypothalamus is important for systemic regulation of blood pressure 142-145; and, 
the nitrergic nerves containing nNOS are responsible for penile erection 137, 146. 
Overall, NO derived from the integration of eNOS and nNOS activities play key 
roles in regulating systemic blood pressure and acutely regulating organ blood 
flow, whereas iNOS-derived NO species are most well recognized for their 
impact on pathogen killing and inflammatory processes 120.   
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Another key function of NO is the regulation of mitochondrial respiration. 
Acutely, NO inhibits respiration by binding and inhibiting cytochrome c oxidase.  
Modulation of respiration by NO is dependent on both mitochondrial activity and 
the O2 level 147, 148. In addition, NO directly regulates the binding and release of 
oxygen with hemoglobin 149 and is able to increase blood flow at sites of very low 
oxygen concentrations 150.  Thus, a key function of NO is to modulate O2 
gradients in cells and tissues by regulating hemoglobin action and by inhibiting 
O2 consumption in respiring mitochondria 119.  Chronic exposure to relatively high 
levels of NO results in mitochondrial biogenesis 151-153, which could reprogram a 
cell or tissue to have a higher metabolic capacity.   
 
NO bioavailability is diminished in obesity 
NO bioavailability is decreased in animal models of obesity 154, 155 and in 
both adult and adolescent humans 156, 157.  Because NO bioavailability is 
dependent upon the balance between its generation and degradation, diminished 
levels of NO in obese states may be due to decreased expression of NOS, 
impairments in NOS activity, decreased NOS substrates or by the reaction of NO 
with reactive species (e.g., superoxide) (Fig 2).  These are discussed below. 
 
NOS expression changes in obesity  
A primary mechanism by which NO bioavailability could be decreased is via 
diminished expression of NOS enzymes (Fig. 2A). In particular, lower eNOS 
abundance is found in both WAT and skeletal muscle of obese humans and
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Figure 2. Mechanisms for decreased endothelial-derived NO in obesity and 
diabetes. Schematic of changes in NOS or NO: (A) Decreased eNOS 
expression commonly occurs in obese and diabetic states. Mechanisms 
proposed for diminished expression include TNF-α-mediated destabilization of 
eNOS mRNA, which may involve eEF1A1.  High levels of NO may regulate 
eNOS abundance through cGMP-mediated or via NF-κB-SNO feedback 
regulatory pathways.  A small 27-nt RNA regulates eNOS expression also, 
although it is not known whether this mechanism is invoked in obesity or 
diabetes.  (B)  Decreased eNOS activity in obesity and diabetes is largely 
attributed to insulin resistance, which may be mediated by free fatty acid (FFA)-
induced activation of TLR2, TLR4, and NF-κB.  In addition, activation of PKCβII 
may diminish Akt signaling, which causes phosphorylation of eNOS on Ser1177.  
Phosphorylation at this site increases NO output by the enzyme.  Hyperglycemia 
may also lead to increased O-GlcNAcylation of eNOS, which decreases Ser1177 
phosphorylation and inhibits its activity. In addition, conditions leading to obesity 
promote upregulation of Cav-1, which is a negative regulator of eNOS, and 
ceramide accumulation disrupts the eNOS-Akt-HSP90 complex, diminishing 
activity of the enzyme. (C) eNOS may also be uncoupled or NO quenched in 
obese and diabetic states.  Diminished levels of substrates and cofactors, such 
as L-arginine or tetrahydrobiopterin (BH4), lead to uncoupling of the enzyme, 
which is commonly associated with the presence of eNOS monomers rather than 
dimers and can produce superoxide instead of NO.  Endogenous inhibitors of 
eNOS such as ADMA are also increased in obese conditions and can promote 
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NOS uncoupling. Elevated production of reactive oxygen species such as 
superoxide can quench NO and result in its oxidation to highly reactive 
peroxynitrite, which damages biomolecules and can oxidize BH4 to BH2. 








rodents 158-162. Factors associated with obesity and diabetes including increased 
shear stress, lysophosphatidylcholine, oxidized LDL, insulin and decreased 
ability to exercise can also regulate eNOS expression 163-167. TNF, which is 
increased in obesity and implicated in the etiology of insulin resistance 168, has 
been found to downregulate eNOS expression and abundance 161, 169-172 by 
decreasing the stability of eNOS mRNA 173, 174, effectively shortening its half-life 
175. This destabilization of the eNOS message has been linked, at least in part, to 
upregulation of elongation factor 1-α1 176.   
Acutely, TNF increases eNOS activity 177, most likely via activation of the PI3K-
Akt 178 and sphingomyelinase/sphingosine-1-phosphate pathways 179, 180.  Such 
diametrically opposite acute versus chronic effects of TNF would appear to 
suggest the potential existence of negative feedback loops that sense high levels 
of NO, leading to downregulation of eNOS.  Indeed, NO donors downregulate 
eNOS expression both in vitro and in vivo, which may involve cGMP and/or S-
nitros(yl)ation of NF-κB 181, 182.  A small, 27-nt RNA has also been shown to be an 
effective feedback regulator of eNOS 183.  Whether such small RNAs or miRNAs 
that regulate NOS expression are induced with obesity is currently unclear. 
Notable changes in the abundance of other NOS isoforms also occur in 
obesity.  The iNOS enzyme increases in abundance in pancreatic β-cells 184, 
aorta 185, skeletal muscle 186, liver 187, 188, and adipose tissue 189-191 of obese 
rodents.  In adipose tissue, the majority of iNOS is derived from infiltrating bone 
marrow-derived macrophages that display a proinflammatory phenotype 189-191.  
However, high levels of TNFα were shown to increase iNOS also in adipocytes, 
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which appears to downregulate UCP2 192; hence, this mechanism could 
contribute to decreases in WAT energy expenditure. In the ventromedial 
hypothalamus, which controls energy intake, diet-induced obesity was associated 
with lower numbers of nNOS-expressing cells 193.  In the aorta, however, nNOS 
was increased in abundance in mice fed a high fat diet.  The induction of nNOS 
was demonstrated to be due to leptin stimulation 194 and may partially 
compensate for the loss of eNOS-mediated vasodilatory action that typically 
occurs in obese, insulin-resistant states. 
 
Changes in eNOS activity in obesity  
Beyond changes in expression, the NO-producing activity of eNOS is 
diminished in metabolic disease (Fig. 2B).  In addition to the required substrates, 
calcium, and cofactors, the activity of eNOS is regulated by protein-protein 
interactions and by several post-translational modifications 132, 195, 196. High fat 
feeding upregulates caveolin-1, a negative regulator of eNOS 197, 198, in the aorta 
of obese rats 199.  Furthermore, ceramide (which is increased in obesity 200) 
promotes disruption of the eNOS-Akt complex from HSP90 201, which increases 
eNOS activity by promoting displacement of caveolin-1 from eNOS 202.    
Conditions of obesity have profound effects on eNOS phosphorylation.  In 
particular, eNOS phosphorylation at serine 1177 (S1177; S1176 in mice), which 
is critical for increasing NO output from the enzyme 203, is diminished in mice by 
nutrient excess 204-207 or high fat feeding 155, 160, 208, 209; studies in obese rats 210-
212 and pigs 213 have shown similar results. This eNOS phosphorylation site is 
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regulated by Akt 214, which is activated by insulin 215. Insulin stimulation of the 
Akt-eNOS pathway could thus be important for regulating post-prandial blood 
flow and nutrient disposition to peripheral tissues. Indeed, insulin resistance in 
the endothelium is sufficient to diminish NO bioavailability and promote 
endothelial dysfunction 216, and impaired eNOS phosphorylation due to insulin 
resistance was shown to be responsible for diminished glucose uptake in the 
skeletal muscle of mice subjected to nutrient excess 217.   
Reasons for diminished phosphorylation of eNOS under conditions of 
nutrient excess and obesity could be due to fatty acid (e.g., palmitate)-mediated 
induction of insulin resistance 155. Elevated free fatty acids lower NO 
bioavailability in cultured cells 218, isolated arteries 219, animal models 220 and 
humans 221, 222.  Insulin resistance due to FFAs may be engendered by activation 
of Toll-like receptor 4 (TLR4) and NF-κB 208, 218 or Toll-like receptor 2 (TLR2) 223.  
Other nutrient conditions inherent to diabetes may also be responsible for loss of 
S1177-eNOS phosphorylation. For example, hyperglycemia causes O-linked N-
acetylglucosamine (O-GlcNAc) modification of eNOS, which diminishes its 
activity 224. Additional mechanisms posited for diminished eNOS phosphorylation 
in the context of obesity include a fatty acid-mediated, yet Akt-independent 
impairment of eNOS phosphorylation 209, and PKCβII-mediated diminishment in 
Akt and eNOS responsiveness to insulin 210, 212.  How these signaling pathways 
integrate to regulate NO production in obesity and diabetes remains to be 




Uncoupling of NOS and quenching of NO in metabolic disease  
The ability of NOS to produce NO is also dependent on its proper 
coupling, which is regulated by multiple cofactors, the ability of the NOS enzyme 
to remain in the dimerized form 225, 226, and post-translational modifications 132, 227-
229 (Fig. 2C).  In particular, the cofactor BH4 is critical to NOS activity, and it has 
been termed a ‘redox sensor’ because elevations in reactive oxygen and nitrogen 
species can result in its depletion 230.  Furthermore, BH4 may reflect the overall 
‘health’ of the endothelium 231. Obese and diabetic states in rodents and human 
cells are associated with decreased BH4 and elevated levels of its oxidized form, 
BH2 231-235. This is important because deficiency in BH4 or elevations in BH2 can 
uncouple NOS, which results in superoxide production from the enzyme and 
increases peroxynitrite generation 227.  Hence, deficiency of BH4 is thought to be 
a major regulator of vascular dysfunction that occurs during obesity and in 
diabetic states.  Indeed, the ratio of BH4 to BH2 is critical in preventing glucose-
induced eNOS uncoupling 236 and replenishment of BH4 pools has proven 
effective in multiple pathological scenarios 227, 228, 237-239. Uncoupling of NOS does 
not appear to be a factor unique to eNOS, however, as nNOS was shown to be 
uncoupled in penile arteries of obese rats, leading to nitrergic dysfunction, which 
was restored by increasing BH4 levels 240.   
Peroxynitrite may be especially critical in promoting NOS uncoupling. The 
3-nitrotyrosine (3-NT) is a typical ‘footprint’ post-translational modification that 
helps identify sites at which eNOS uncoupling might have occurred, and it is 
worth noting that this modification is observed in abundance in the context of 
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obesity and diabetes (e.g., 160, 232, 241, 242).  Patients with diabetes had diminished 
flow-mediated dilation of coronary arterioles and increased 3-NT protein adducts 
that colocalized with caveolae, demonstrating a dysfunction of the endothelium 
associated with elevated peroxynitrite production 243.  Interestingly, endothelial 
dysfunction in diabetic patients was rescued by sepiapterin supplementation 243, 
inferring that peroxynitrite may disrupt eNOS function not only by caveolar 
disruption, but by depleting BH4.  This would be consistent with multiple studies 
showing that elevated levels of reactive species (in addition to peroxynitrite, such 
as superoxide produced from NADPH oxidase) promote eNOS uncoupling 244-248. 
Nevertheless, the specific contribution of peroxynitrite and other reactive species 
to endothelial function is still unclear. Some studies suggest that rather than 
contributing to the uncoupling of eNOS, superoxide derived from NADPH oxidase 
activates the enzyme 249. Hence, inhibited eNOS function perceived under 
conditions of oxidative stress could be due in part to the quenching of NO and 
not to uncoupling of the enzyme per se.   While this would be consistent with the 
near diffusion-limited reaction rate of NO with superoxide (which is reported to be 
as high as 1.9 × 1010 M-1 s-1) 250, the evidence for a deleterious role of uncoupled 
NOS should not be underestimated, and multiple other factors beyond BH4 
depletion, such as asymmetric dimethyl arginine (ADMA) levels, insufficient L-
arginine levels or glutathio(ny)lation of the eNOS enzyme, can promote eNOS 
uncoupling and endothelial dysfunction 132, 251-254. That levels of ADMA are 
positively correlated with insulin resistance and diabetes, and that arginine 
supplementation overcomes this competitive inhibition 255 further suggests that 
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eNOS uncoupling or inhibition are major contributors to the development of 
metabolic diseases associated with obesity.    
Despite these findings, it is unclear whether obesity itself decreases NO 
availability.  The fact that obesity in humans is associated with decreased blood 
flow in response to methacholine 256, bradykinin 257, 258, substance P and 
acetylcholine 258, shear stress 259, and insulin 260, 261 appears to suggest that the 
obese condition is somehow linked causally with diminished vascular NO 
bioavailability. Several studies showing similar results lend credence to this 
hypothesis 158, 262-273.  However, the question remains: Is loss of NO production 
somehow due to excess adiposity, or is its etiology derived from those conditions 
commonly associated with obesity? Interestingly, endothelial dysfunction was 
found to occur in morbidly obese humans only in the presence of insulin 
resistance 274. And, severely obese humans, in the absence of insulin resistance, 
showed better flow-mediated dilation compared with normal and obese insulin-
sensitive subjects 275.  Furthermore, capillary recruitment has been shown to be 
higher in overweight compared with lean individuals 276.  This suggests that the 
maintenance of a metabolically benign form of obesity is possible and that either 
insulin resistance or conditions directly linked with the insulin resistant phenotype 
(e.g., dyslipidemia, inflammation, hyperglycemia) are to blame for loss of NO 
bioavailability during obesity.  Collectively, these findings raise multiple 
questions:  What determines how the metabolically benign versus harmful forms 
of obesity develop?; How does NO affect obesity and insulin resistance?; What is 
the relevance of changes in NOS isoform abundance, (some of which go in 
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diametrically opposite directions (e.g., eNOS vs. iNOS)), in the development of 







Extensive evidence shows that obesity is a robust risk factor for the development 
of T2D, yet the mechanisms by which obesity increases the risk of T2D remain 
unclear. Recent studies suggest that endothelial dysfunction, characterized by a 
decrease in nitric oxide (NO) production, is pivotal in the progression of metabolic 
disease. The endothelium is a central regulator of insulin sensitivity and is the 
first tissue to become insulin resistant. In addition, it has been reported that 
deletion of eNOS is associated with adiposity, insulin resistance and impaired 
fatty acid oxidation. Nevertheless, the role of eNOS in regulating metabolism is 
not well understood. The overall goal of my work is to understand how NO 
regulates metabolism. We propose that during nutrient excess decreased 
vascular-derived NO bioavailability is a critical step that leads to the development 
of metabolic dysregulation. Specifically, we hypothesize that an increase in 
NO derived from eNOS prevents diet-induced obesity by promoting 
adipose tissue browning and increasing systemic metabolism. To determine 
effects of nutrient excess on tissues critical to obesity-related insulin resistance, 
we examined nutrient excess-induced metabolic changes occurring in adipose 
tissue. As discussed in Chapter II, we found changes consistent with 
mitochondrial remodeling and loss of mitochondrial bioenergetic capacity in 
adipose tissue. Further we show that obesity induces profound decreases in 
eNOS abundance. To assess the significance of eNOS downregulation, we 
investigated whether increasing eNOS expression was sufficient to prevent 
obesity-related metabolic consequences (Chapter III, Aim I). After studying the 
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anti-obesogenic effects of eNOS, we examined how overexpression of eNOS 
affects systemic metabolism (Chapter IV, Aim II). Our findings reveal an 
important role of NO in regulating metabolism and suggest that increasing NO 
could prevent diet-induced obesity. In addition, our findings support the view that, 
while obesity and insulin resistance are closely associated they remain distinctly 





METABOLIC REMODELING OF WHITE ADIPOSE TISSUE IN OBESIT. 
 
Introduction 
The increasing prevalence of obesity is a principal health concern 
worldwide. In 2008, approximately 1.5 billion adults aged 20 years or older were 
overweight, and 10% were obese 1. In the US, more than one-third of the adult 
population is currently obese (BMI >30), and 68% have a BMI>25 277; these 
numbers are expected to increase by more than 50% by the year 2025 7.  These 
statistics are cause for alarm. Obesity is a powerful predictor of insulin resistance 
4 and a major risk factor for several common medical conditions, including type 2 
diabetes (T2D), cardiovascular disease, non-alcoholic fatty liver and gallstones, 
Alzheimer’s disease, and some cancers 278.  
While lack of exercise is an undeniable risk factor for weight gain 278-280, 
excessive caloric intake appears to be one of the key factors fueling the obesity 
epidemic. In the past three decades, the average consumption of calories in the 
US has increased by at least 200 kcal/d per person, which is partly attributable to 
an increase in the intake of energy-dense foods 8-10, 281. Such poor dietary habits 
negatively affect metabolic homeostasis, which could not only promote obesity, 
but the development of obesity-related co-morbidities as well. Despite the
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simplicity of the apparent remedy (i.e., decreasing caloric intake), treatment of 
obesity remains a challenging crisis facing the health care system. Losing weight 
via caloric restriction faces multiple conceptual challenges: these include an 
evolutionarily engendered guard against starvation and low fat mass 7, 31 and a 
propensity to increase caloric efficiency during dieting 32, 33.  While several 
approaches to combat obesity have been approved for clinical use, including 
medications that reduce caloric intake or absorption and bariatric surgery, these 
approaches in many cases show marginal long-term efficacy or have 
unacceptable or overtly dangerous side effects 7.  Thus, recent strategies to 
modulate obesity have begun to target tissues that naturally regulate energy 
metabolism.   
Increasing energy expenditure by modulating adipose tissue activity has 
become an especially attractive target for therapy.  Guided by the fact that adult 
humans maintain small depots of brown fat capable of burning significant 
amounts of calorific energy 57, multiple studies focused on the physiological and 
molecular mechanisms regulating the thermogenic capacity of adipose tissue.  
These studies show that adaptive thermogenesis in brown fat can be a powerful 
regulator of systemic energy metabolism.  However, the relatively small amount 
of brown adipose (less than 0.4% of body weight) compared with white adipose 
tissue (WAT; which can comprise 40% or more of the body weight of an obese 
human) suggests that WAT may be a more tangible target. Interestingly, white 
adipose depots, which typically function to esterify free fatty acids (FFA) and 
store excess lipids, have the capacity to develop brown adipose-like tissue 
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capable of modulating systemic metabolism and preventing obesity and insulin 
resistance 282.   
While the phenomenon of adipose “browning” is an exciting area of 
research, there is also considerable interest in understanding the metabolic 
changes that occur in WAT with obesity.  It has become increasingly clear that 
conditions of nutrient excess promote a “whitening” of adipose tissue 
characterized by decreases in mitochondrial abundance 93, 283, 284.  Hence, while 
promoting “browning” is one way to positively modulate metabolism, decreasing 
adipose tissue “whitening” could in principle prevent the dysregulation of 
systemic metabolism caused by obesity. Indeed, the therapeutic actions of 
thiazolidinediones such as rosiglitazone and pioglitazone have been suggested 
to be due to their ability to prevent loss of mitochondria or increase mitochondrial 
function in WAT 284, 285.  Nevertheless, the metabolic changes occurring during 
adipose tissue whitening have not been well-characterized, in part because these 
metabolic changes have been difficult to dissect from other sequelae of obesity 
such as adipose tissue inflammation.   
In this study, we examined both the systemic and WAT-specific changes 
in metabolism in a common model of diet-induced obesity—the C57BL/6J mouse 
fed a high fat diet (60% kcal from fat).  Our data indicate that mitochondrial 
remodeling, leading to decreases in mitochondrial oxidative phosphorylation and 
substrate oxidation, precedes the infiltration of inflammatory cells such as 
macrophages.  The changes apparently precede overt loss of mitochondrial 
mass and coincide with decreases in PGC1α and dysregulation of lipid and 
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amino acid metabolism.  In addition, we find ultrastructural and biochemical 
changes consistent with autophagy and mitochondrial remodeling, the onset of 
which also appears to precede the infiltration of macrophages. These findings 
have important implications for our understanding of the effects of obesity on 
adipose tissue metabolism and suggest that inhibiting the metabolic changes that 
contribute to adipose whitening could form the basis for novel therapies to 
combat metabolic disease.   
 
Experimental Procedures 
Animal studies: All procedures were approved by the University of Louisville 
Institutional Animal Care and Use Committee. C57BL/6J (wild-type; WT) mice 
were purchased from The Jackson Laboratory (Bar Harbor, ME). At 8 weeks of 
age, male mice were placed on either a 10% low fat diet (LFD; Research Diets, 
Inc., #D12450B) or a 60% high fat diet (HFD; Research Diets Inc., #D12492) for 
6 or 12 weeks. Water and diet were provided ad libitum. Body weights were 
recorded weekly.  
 
Metabolic phenotyping: Body composition was measured by dual-energy X-ray 
absorptiometry using a mouse densitometer (PIXImus2; Lunar, Madison, WI), 
and whole body energy expenditure, respiratory exchange ratio, food 
consumption, and locomotion, ambulatory and fine movements were measured 
using a physiological/metabolic cage system (TSE PhenoMaster System, Bad 
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Homberg, Germany) 286.  Glucose and insulin tolerance tests and plasma levels 
of insulin were measured as described in Sansbury et al 286.  
 
Adipocyte size measurements: Adipose tissue was excised at the time of 
euthanasia, and wet weight was recorded. All adipose tissue was either snap-
frozen at –80°C or fixed in 10% formalin (Leica), paraffin embedded, and 
sectioned. Sections were stained in hematoxylin and eosin. Adipocyte cross-
sectional area and size distribution was determined using Nikon Elements. 
Adipose tissue sections were assessed for crown-like structures as described 
previously 287.   
 
Adipose tissue metabolite profiling: WAT from the epididymal fat pads of mice 
fed a LFD or HFD for 6 weeks were used for these analyses.  Prior to tissue 
collection, mice were fasted for 16 h.  After euthanasia, the adipose tissue was 
removed and immediately snap-frozen in liquid nitrogen. Relative metabolite 
abundance was then measured by GC/MS or LC/MS as described before 286. 
Metabolites with missing values were imputed by replacing missing values with 
half of the minimum positive value in the original data.  Metabolites with greater 
than 57% of values missing were omitted from the analysis. After a generalized 
logarithm transformation, data were autoscaled, i.e., mean-centered and divided 
by the standard deviation of each variable. This step was performed to transform 
the intensity values so that the distribution was more Gaussian. T-test statistical 
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comparisons were then performed.  Univariate (e.g., volcano plots), multivariate 
(e.g., PLS-DA), and cluster (heatmap and dendogram) analyses were then 
performed. Most analyses were performed using Metaboanalyst 2.0 software 
(http://www.metaboanalyst.ca/) 288; z-score plots were constructed in GraphPad 
5.0 software using data derived from volcano plot analysis.    
 
Adipose tissue bioenergetic measurements: The oxygen consumption rate 
(OCR) of intact WAT explants was measured using a Seahorse XF24 analyzer 
(Seahorse Bioscience, Billerica, MA) as described previously 286. At least two 
replicates from each animal were used for the assay. After baseline 
measurements, the maximal OCR was measured by exposing the explants to 
carbonyl cyanide-4-(trifluoromethoxy)phenylhydrazone (FCCP) (10 µM).  The 
non-mitochondrial OCR was measured following injection of antimycin A (25 μM) 
and rotenone (5 μM).  
 
Citrate synthase acitivity assay: Citrate synthase activity was measured in 100 
mM Tris-HCl, pH 8.0, containing 1 mM EDTA, 1 mM 5', 5'-Dithiobis 2-
nitrobenzoic acid (DTNB), 10 mM acetyl-CoA. The reaction was initiated by 
addition of 10 mM oxaloacetate. Cuvettes were warmed to 37°C, and upon 
addition of 10 μg of protein from WAT lysates, absorbance at 420 nm was 
measured for 10 min. Activity was expressed as nmoles/min/μg protein.  
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Expression analyses: For quantitative RT-PCR, RNA was extracted from 
tissues using the RNeasy lipid tissue kit (Qiagen), followed by cDNA synthesis. 
Real-time PCR amplification was performed with SYBR Green qPCR Master Mix 
(SA Biosciences) using a 7900HT Fast Real-Time PCR System (Applied 
Biosystems) and commercially available primers for il1, tnfa, il6, arg1, il10, ym1, 
hif1a, emr1, pgc1a, cytc, sirt1, sirt3, pdk4, cpt1a, cpt1b, cox7a1, hprt, and idh3a 
(SA Biosciences). Relative expression was determined by the 2−ΔΔCT method. M1 
macrophages in WAT were measured by flow cytometry using well-validated 
surface markers as shown previously 287.   
To measure protein abundance, WAT homogenates were prepared 
exactly as described in Horrillo et al 289. Equal amounts of protein were separated 
by SDS-PAGE, electroblotted to PVDF membranes, and probed using primary 
antibodies according to the manufacturers’ protocol.  The antibodies used were: 
ALDH2 (Abcam), Sirt3 (Cell Signaling), MitoProfile® Total OXPHOS Rodent WB 
Antibody Cocktail (Mitosciences), COX4I1 (Cell Signaling), GAPDH (Cell 
Signaling), Parkin (Abcam), Pink1 (Cell Signaling), p62 (Cell Signaling), LC3 
(Cell Signaling), protein-ubiquitin (Cell Signaling) and α-tubulin (Cell Signaling).  
Fluorescent or HRP-linked secondary antibodies (Invitrogen) were used for 
detection and visualized with a Typhoon 9400 variable mode imager (GE 
Healthcare). Band intensity was determined using Image Quant TL® software. 
Relative mitochondrial DNA (mtDNA) measurements: Mitochondrial 
abundance in adipose tissue was estimated by measuring the mtDNA 
abundance relative to nDNA, essentially as described previously 290. Total DNA 
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was isolated from WAT using a QIAamp DNA Mini Kit (Qiagen).  Aliquots of 25 
mg tissue were homogenized followed by overnight digestion in Proteinase K at 
55°C.  Following isolation, relative amounts of mtDNA and nuclear DNA (nDNA) 
were compared using quantitative RT PCR.  In each assay 2 ng of DNA was 
used with specific primers for cytochrome b (mtDNA) and β-actin (nDNA).   
Sequences for the primer sets used were: cytochrome b, 5’-
TTGGGTTGTTTGATCCTGTTTCG-3’ and 5’-
CTTCGCTTTCCACTTCATCTTACC-3’; β -actin, 5’-
CAGGATGCCTCTCTTGCTCT-3’ and 5’-CGTCTTCCCCTCCATCGT-3’.  
 
Electron microscopy: Adipose tissues were fixed with 3% glutaraldehyde in 0.1 
M sodium phosphate buffer (pH 7.4) for 4 h at room temperature (25 °C). Tissues 
were then post-fixed with 1% osmium tetroxide for 1 h, dehydrated,  embedded in 
Embed-812 plastic (Electron Microscopy Sciences). Ultrathin (50-70 nm) sections 
were stained with uranyl acetate and Reynolds lead citrate, and electron 
micrographs were taken using a Philips CM10 transmission electron microscope 
operating at 80 kV. 
 
Statistical analyses: Data are mean ± SEM.  Unpaired Student’s t test was 
used for direct comparisons. Statistical analyses for metabolomic datasets were 





High fat diet leads to increased adiposity and altered systemic metabolism. 
Wild-type C57BL/6J mice were placed on a LFD or HFD for 6 weeks. Significant 
weight gain occurred as early as 1 week on HFD, and the change in total body 
mass was nearly 10 g by 6 weeks on the diet (Fig. 3A). Food and water intake 
were not significantly different between groups (Fig. 3B,C). Dexascan analysis 
showed a 2-fold increase in fat mass and a concomitant decrease in lean mass 
in HF-fed mice (Fig. 3D,E).  These results are typical of this commonly utilized 
model of diet-induced obesity, e.g., see 155, 286.  
To determine how diet affects systemic metabolism, mice fed either LFD or HFD 
for 6 weeks were placed in metabolic chambers, and their oxygen consumption 
(VO2), carbon dioxide production (VCO2), and physical activity were measured. 
As shown in Fig. 3F and G, average VO2 and VCO2 values decreased in HF-fed 
mice compared with mice fed a LFD. The respiratory exchange ratio (RER) was 
also decreased in mice fed a HFD compared with mice fed LFD (Fig. 3H).  
Physical activity, measured by total beam breaks (Fig. 3I), ambulatory counts 
(Fig. 3J), and fine movements (Fig. 3K), was not significantly different between 
groups, although the group fed a HFD appeared to show a trend toward 
decreased physical movement. Similar to previous studies 286, mice fed a HFD 
also demonstrated worsened glucose and insulin tolerance (Fig. 4) as well as a 
significant increase in plasma insulin levels (WT LFD, 151±71 pg/ml  vs. WT 
HFD, 2690±593 pg/ml, n = 3 per group, p<0.05). 
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Figure 3. Effects of high fat diet on weight gain, adiposity and systemic 
metabolism. Male WT C57BL/6J mice were fed a low fat diet (LFD, 10% kcal 
fat) or high fat diet (HFD, 60% kcal fat) for 6 weeks and the following 
measurements were recorded: (A) mouse weights during 6 weeks of feeding, n = 
20 per group; (B) food intake, n = 7 per group; (C) water intake, n = 7 per group; 
(D) representative DexaScan images; (E) percentages of lean mass and body 
fat, n = 10 per group; and (F) average oxygen consumption (VO2); (G) average 
carbon dioxide production (VCO2); (H) respiratory exchange ratio (RER); (I) total 
activity level; (J) ambulatory counts; and (K) fine movements. n = 7 per group; 







Figure 4. Glucose and insulin tolerance in mice fed low fat or high fat diets. 
After 6 weeks of a low fat (LFD) or high fat diet (HFD), glucose tolerance and 
insulin sensitivity were examined: (A) Glucose tolerance test (GTT); (B) GTT 
area under the curve (AUC); (C) insulin tolerance test (ITT) shown as % of 





Macrophage infiltration does not occur until after 6 weeks of HFD. To 
measure the metabolic effects of obesity on adipocytes in the intact adipose 
organ, effects of inflammatory cells such as macrophages must first be ruled out 
or otherwise delineated.  To examine effects of HFD on macrophage infiltration, 
we placed mice on LFD or HFD for 6 and 12 weeks and measured adipocyte 
size, crown-like structures indicative of macrophage infiltration, and the 
expression of inflammatory genes.  As shown in Fig. 5A–C, mice fed a HFD for 6 
and 12 weeks showed a 3–4-fold increase in adipocyte size when compared with 
LFD controls.  While sections of WAT derived from mice fed a HFD for 12 weeks 
showed obvious increases in crown-like structures, WAT from mice fed HFD for 6 
weeks showed minimal changes in such structures. This suggested that with 6 
weeks of HFD, there was minimal macrophage accumulation.  Indeed, the 
expression of emr1—a marker of macrophages—as well as that of other 
inflammatory genes was not changed with 6 weeks of HFD, and hypoxia was not 
evident as measured by expression of Hif1a (Fig. 5D).  Moreover, the abundance 
of M1 macrophages in adipose tissue stromal vascular fractions was not different 
between mice fed the different diets (F4/80+/CD11c+/CD301- cells as F4/80+ 
cells: LFD 37.4±3.5; HFD, 45.9±1.8; n = 9–10 per group, p>0.05.).  Most likely, 
the modest, insignificant increase in Tnfa is due to adipocytes, which have been 
shown to produce TNF-α 291, 292.  Collectively, these data show that after 6 weeks 
of HFD, there is an increase in adipocyte size without significant changes in 




Figure 5. Effect of HFD on adipose tissue expansion and inflammation. 
Morphological and molecular changes in adipose tissues: (A) Representative 
hematoxylin and eosin stains of epididymal adipose tissue of mice fed a LFD or 
HFD for 6 or 12 weeks; (B) average size of adipocytes; (C) adipocyte size 
distribution; and (D) qRT-PCR analyses of markers of inflammation in adipose 
tissues from mice fed a LFD or HFD for 6 weeks. CLS, crown-like structure; n = 





Obesity alters the metabolite profile of adipose tissue.  To examine the effect 
of obesity on adipose tissue metabolism, epididymal WAT from mice fed a LFD 
or HFD for 6 weeks was subjected to unbiased metabolomic analysis.  The 
relative concentrations of adipose metabolites were measured by mass 
spectrometry and queried against the Metabolon reference library. Partial least 
squares-discriminant analysis (PLS-DA) showed that the LFD samples clearly 
separate from HFD samples (Fig. 6A), and cluster analysis showed that the 
abundance of most metabolites was decreased in the HFD group compared with 
the LFD group (Fig. 6B).  Out of the 191 metabolites measured, 82 were found to 
be significantly different (p<0.05) in the WAT of mice fed a HFD compared with 
that of adipose from mice fed a LFD.  Volcano plot analysis showed that the 
levels of 79 metabolites decreased significantly and only 3 metabolites increased 
significantly with HF feeding (Fig. 6C and Table 1).  To examine and visualize the 
data in the biological context of metabolic pathways, metabolites that were 
statistically different in each group were analyzed using the MetPA tool of 
Metaboanalyst 2.0 software.  Pathways were calculated as the sum of the 
importance measures of the matched metabolites normalized by the sum of the 
importance measures of all metabolites in each pathway 288. As shown in Fig. 
6D, the highest pathway impact values were related with branched chain amino 
acid (BCAA) metabolism (i.e., Val, Leu, and Ile metabolism) and Phe, Tyr and 
Trp metabolism. Significant changes were also observed in His metabolism as 
well as Gly and Ser metabolism. Glycerophospholipid metabolism showed the 
most significant change with HF feeding. To further delineate changes in 
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Figure 6. Metabolomic analyses of adipose tissue.  Metabolomic analyses of 
epididymal adipose tissue metabolites from WT mice fed a LFD or HFD for 6 
weeks: (A) Multivariate analysis: partial least squares-discriminant analysis (PLS-
DA); (B) Hierarchial clustering: Heatmap and dendogram; (C) Univariate 
analysis: Volcano plot of metabolites. Those metabolites that significantly 
increased are in the quadrant shaded red and those that significantly decreased 
are shaded green (p<0.05, t-test). A list of these metabolites can be found in 
Table 1; (D) Metabolites found to be significantly different were subjected to 
pathway impact analysis using Metaboanalyst MetPA and the Mus musculus 
pathway library. Fisher’s exact test was used for overrepresentation analysis, 
and relative betweenness centrality was used for pathway topology analysis. n = 






Table 1. List of adipose tissue metabolites that changed significantly in 
high fat-fed mice. 
Metabolite 
Fold 
change p value FDR 
threonine 0.54948 2.03E-08 3.57E-06 
leucine 0.45023 6.26E-08 5.51E-06 
ergothioneine 0.25885 7.34E-07 4.31E-05 
tyrosine 0.44838 2.05E-06 9.03E-05 
valine 0.34372 3.68E-06 0.00013 
phenylalanine 0.35614 4.73E-06 0.000139 
phosphoethanolamine 0.56087 5.51E-06 0.000139 
proline 0.55922 6.39E-06 0.000141 
pantothenate 0.41779 1.70E-05 0.000333 
lysine 0.49838 2.14E-05 0.000376 
xanthine 0.5918 3.02E-05 0.000484 
1,5-anhydroglucitol (1,5-AG) 0.32145 3.73E-05 0.000547 
isoleucine 0.46664 4.36E-05 0.000591 
betaine 0.48746 4.84E-05 0.000608 
asparagine 0.63104 7.38E-05 0.000792 
mead acid (20:3n9) 0.37579 7.54E-05 0.000792 
flavin adenine dinucleotide (FAD) 0.46937 7.75E-05 0.000792 
3-dehydrocarnitine 0.33055 8.10E-05 0.000792 
tryptophan 0.49615 9.37E-05 0.000868 
carnitine 0.66176 0.000107 0.00094 
methionine 0.49975 0.000175 0.001466 
serine 0.50099 0.000188 0.001502 
histamine 0.26069 0.000204 0.001523 
arginine 0.6417 0.000208 0.001523 
glycerophosphoethanolamine 1.5377 0.000292 0.001997 
glutamine 0.75187 0.000295 0.001997 
cholesterol 0.7317 0.000403 0.002579 
C-glycosyltryptophan 0.53405 0.00041 0.002579 
cis-vaccenate (18:1n7) 0.49012 0.000438 0.002608 
citrulline 0.73299 0.000454 0.002608 
phosphate 0.59509 0.000459 0.002608 
urea 0.38721 0.000489 0.002689 
17-methylstearate 0.37705 0.000566 0.00302 
nicotinamide 0.55648 0.000601 0.003114 
hydroxyisovaleroyl carnitine 0.54575 0.000634 0.00319 
mannose-6-phosphate 0.20024 0.001153 0.00549 
histidine 0.38909 0.001154 0.00549 
choline 0.60096 0.001218 0.005641 
palmitoleate (16:1n7) 0.51634 0.001386 0.006253 
glycerol 0.50143 0.001522 0.00668 
taurine 0.75975 0.001556 0.00668 
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glucose-6-phosphate (G6P) 0.29197 0.001647 0.006899 
1-stearoylglycerophosphoinositol 0.49031 0.002247 0.009195 
uracil 0.44141 0.002558 0.010175 
hypoxanthine 0.35895 0.002619 0.010175 
isobutyrylcarnitine 0.4573 0.002703 0.010175 
isopalmitic acid 0.28706 0.002733 0.010175 
uridine 0.53462 0.002775 0.010175 
scyllo-inositol 0.39204 0.00328 0.011781 
S-adenosylhomocysteine (SAH) 0.49132 0.003745 0.013182 
1-oleoylglycerophosphoethanolamine 0.47672 0.004631 0.015981 
1-palmitoylglycerophosphoethanolamine 0.58479 0.004838 0.016374 
glycerol 3-phosphate (G3P) 0.59732 0.005149 0.017099 
1-palmitoylglycerophosphoinositol 0.66829 0.005556 0.01811 
nonadecanoate (19:0) 0.47985 0.006228 0.01993 
cysteine 0.5292 0.007339 0.023067 
eicosenoate (20:1n9 or 11) 0.40267 0.00756 0.023275 
10-nonadecenoate (19:1n9) 0.45235 0.00767 0.023275 
cysteine-glutathione disulfide 0.5291 0.008825 0.026327 
palmitoyl sphingomyelin 0.60227 0.009257 0.027153 
choline phosphate 0.74957 0.010514 0.030335 
N-acetylglucosamine 6-phosphate 0.39909 0.012184 0.034588 
1-arachidonoylglycerophosphoinositol 0.48542 0.012459 0.034806 
2-hydroxyglutarate 0.39816 0.013183 0.036253 
inosine 0.45019 0.013616 0.036867 
glycerol 2-phosphate 0.39934 0.014415 0.038439 
cytidine 0.59371 0.015663 0.040621 
stearoyl sphingomyelin 1.5942 0.015695 0.040621 
urate 0.49862 0.020514 0.052327 
1-arachidonoylglycerophosphoethanolamine 0.57421 0.021629 0.054382 
1-palmitoleoylglycerophosphoethanolamine 0.26907 0.023675 0.058687 
stearidonate (18:4n3) 0.65008 0.024231 0.05923 
lactate 0.63047 0.025519 0.061036 
alpha-tocopherol 0.33155 0.025663 0.061036 
oleate (18:1n9) 0.6828 0.030736 0.072127 
2-methylbutyroylcarnitine 0.42844 0.036105 0.083611 
palmitate (16:0) 0.71324 0.03874 0.088549 
isovalerylcarnitine 0.39518 0.040257 0.090836 
guanosine 0.52357 0.044904 0.10004 
succinate 1.3363 0.047935 0.10531 
adenosine 0.73547 0.048468 0.10531 
Wild-type (WT) mice were fed a low fat or high fat diet (LFD or HFD, 
respectively) for 6 weeks. Epididymal adipose tissue was then subjected to LC 
or GC mass spectrometric analysis.  Those metabolites found to be significantly 




metabolites, we examined those metabolites that were either significantly 
elevated or those that were decreased in abundance by more than 60%.  As 
shown in Fig. 7, stearoyl sphingomyelin, glycerophosphoethanolamine, and 
succinate were the only metabolites that increased in abundance in WAT derived 
from HF-fed mice.  The majority of metabolites that decreased by >60% 
belonged to the lipid and amino acid superfamilies.   
 
The effect of obesity on mitochondrial oxygen consumption and 
mitochondrial remodeling in WAT explants. The increase in succinate found 
in our metabolomic analyses suggested that HFD may alter adipose tissue 
bioenergetics. Importantly, these changes occurred in the absence of 
inflammatory cell infiltration (see Fig. 5), which could otherwise confound 
adipocyte-specific changes in metabolism. To determine how obesity affects 
adipose tissue mitochondrial function, WAT explants from mice fed a LFD or 
HFD were subjected to extracellular flux analysis.  As shown in Fig. 8A and B, 
the apparent basal mitochondrial oxygen consumption rate of adipose tissue 
derived from mice fed a LFD was >2-fold higher when compared with adipose 
explants derived from HF-fed mice (p<0.05); however, statistical significance in 
OCR between groups was lost upon exposure of explants to FCCP (Fig. 8C). 
This appeared to be largely due to an enhanced FCCP response in WAT 
explants from obese mice.  As shown in Fig. 8D, explants derived from mice fed 




Figure 7. Z-score plot analysis of metabolite changes in adipose tissue 
from high fat fed mice. Mice were fed a LFD or HFD for 6 weeks. Data are 
shown as standard deviations from the mean of LFD. Only the metabolites that 
increased significantly and those that decreased by >60% are shown. Each point 












extracellular acidification rate (ECAR, a measure of the coupling between 
glycolysis and glucose oxidation) was observed. 
Although citrate synthase activity was decreased by more than 50% in 
WAT derived from these mice (Fig. 8E), which suggested a decrease in 
mitochondrial abundance, relative abundance of mtDNA, as assessed by qPCR 
of mtDNA and nDNA, was not changed after 6 weeks of diet (Fig. 8F).  From our 
protein determination measurements, we calculated that the yield of protein per 
wet weight is diminished by 43% in adipose tissue from high fat-fed mice (µg 
protein/mg wet weight: 6 wk LFD, 10.86±1.70; 6 wk HFD, 6.21±1.28; n = 10–12 
per group). Applying this information to our data would then shift the OCR curves 
to levels near those observed in explants from low fat-fed mice; which suggested 
no overall change in oxygen consumption per mitochondrion. However, the 
expression of cox7a1, a subunit in the electron transport chain per mg protein, 
was increased more than 2-fold in adipose tissue from mice fed a HFD, whereas 
pgc1a, sirt3, and pdk4 expression were decreased (Fig. 8G) which indicated 
mitochondrial remodeling with preserved function.       
To examine how WAT mitochondria change with obesity, we assessed the 
relative abundance of several mitochondrial complex proteins as well as 
mitochondrial matrix proteins. Although no changes in mitochondrial protein 
abundance were observed at 6 weeks of HFD, the protein levels of NDUFB8, 
SDHB, and COX4I1—subunits of complexes I, II, and IV, respectively—were 




Figure 8. Obesity-related energetic changes in white adipose tissue.  
Metabolic analysis of adipose tissue from mice fed a LFD or HFD for 6 weeks: 
(A) Extracellular flux analysis: After three basal oxygen consumption rate (OCR) 
measurements, FCCP (10 µM) was injected, followed by injection of antimycin A 
(AA, 25 μM) and rotenone (Rot, 5 μM). The apparent contribution of the non-
mitochondrial OCR to the total OCR is indicated by the gray box.  (B) Apparent 
basal mitochondrial OCR: The stabilized non-mitochondrial OCR achieved after 
AA+Rot treatment was subtracted from the basal OCR to calculate the rate of 
mitochondrial oxygen utilization in each explant; (C) FCCP-stimulated OCR: The 
FCCP-stimulated OCR was calculated by subtracting the non-mitochondrial OCR 
from maximal rate achieved after FCCP addition; (D) FCCP response: the FCCP 
response in each explant was calculated using the equation: (OCRMAX/OCRBASAL) 
× 100; n = 10 mice per group; (E) citrate synthase activity, n = 3-6 mice per 
group; (F) Relative mtDNA content, n = 6 per group; and (G) expression of 












Figure 9. Obesity-related changes in mitochondrial protein abundance in 
white adipose tissue.  Analysis of adipose tissue from mice fed a LFD or HFD 
for 6 or 12 weeks: (A) Representative Western blots of mitochondrial matrix 
proteins and respiratory chain subunits; (B) Quantification of ALDH2; (C) 
Quantification of Sirt3; (D) Quantification of respiratory subunit abundance.  All 
blots were normalized to ATP5A, which showed no change in abundance in any 







ALDH2 and Sirt3 showed similar trends, with ALDH2 decreasing significantly by 
12 weeks of HFD. 
 
Assessment of adipose tissue ultrastructure. To examine in greater detail the 
subcellular changes that occur in adipose tissue of nutrient-stressed animals, we 
examined adipocyte ultrastructure using electron microscopy. As shown in Fig 
8A, adipose tissue from mice fed a LFD showed mitochondria with three distinct 
morphologies: a round morphology of small size that was located near the 
nucleus (Fig. 10A-i,ii), a typical elongated shape up to ~0.7 μm in length located 
in small protrusions along the adipocyte cell membrane (Fig. 10A-iii), and 
extremely long mitochondria (up to 5 μm and above) that were located in 
juxtaposition to the fat locule (Fig. 10A-iv).  In adipocytes derived from HF-fed 
mice, autophagosomes—defined by a double-membrane and comprising 
cytoplasmic constituents—were found next to mitochondria (Fig. 10B-i), and 
large vacuoles of electron-dense material were present adjacent to 
autophagosomes (Fig. 10B-ii,iii). In addition, many mitochondria in adipose 
tissues from HF-fed mice appeared to be undergoing fission (Fig. 10B-iv,v).   
 
Effects of HFD on autophagy. Changes in citrate synthase and mitochondrial 
proteins combined with the ultrastructural alterations found in adipose tissue 




Figure 10. Ultrastructure of white adipose tissues from lean and obese 
mice. Representative transmission electron micrographs of epididymal adipose 
tissues derived from mice fed a LFD or HFD for 6 weeks. (A) Ultrastructure of 
mitochondria in adipose tissues from LF-fed mice: (i) micrograph of adipocytes in 
areas close to the nucleus; (ii) higher magnification of panel i; (iii) a cytosolic 
compartment containing a mitochondrion found protruding into the fat locule; and 
(iv) an elongated mitochondrion in juxtaposition to the fat locule. (B) 
Ultrastructure of adipose tissue derived from HF-fed mice: (i) An elongated 
mitochondrion next to an autophagosome; (ii) an autophagosome in close 
proximity to a vacuole containing electron-dense material; (iii) magnified image of 
panel ii; (iv) protrusion of cytosolic compartment containing an atypical 
mitochondrion; and (v) mitochondrion that appears to be undergoing fission. 
Asterisks (*) indicate autophagosomes; small arrows indicate collagen; 











in WAT. To examine this possibility, we measured markers of mitophagy and 
autophagy in adipose tissues from mice fed a LFD or HFD.  The  E3 ubiquitin 
ligase Parkin, which has been shown to accumulate in mitochondria destined for 
degradation 293, was increased 2.3-fold by 6 weeks of HFD and nearly 2-fold by 
12 weeks of HFD (Fig. 11A,B).  Furthermore, the kinase Pink1—critical for 
identifying mitochondria destined for autophagy 293—was also increased by 
nearly 40% with HFD. Combined with the presence of autophagosomes and 
mitochondrial alterations observed by EM (Fig. 10), this suggests that autophagy 
may be involved in the metabolic remodeling of adipocytes in the expanding 
adipose organ and protein indicators of autophagy were examined. As shown in 
Fig. 11C–H, levels of p62 and LC3-I were diminished significantly and the LC3-
II/LC3-I ratio was increased more than 2-fold in mice fed a HFD for 6 weeks in 
comparison with those placed on LFD.  There was no significant difference in 
total protein abundance of protein-ubiquitin and LC3-II.  
 
Discussion 
This study demonstrates coordinated changes in adipose tissue 
metabolism that contribute to the “whitening” program during obesity. Using 
metabolomics analysis, we identified that lipid and amino acid metabolism was 
significantly significantly changed by HFD.  Importantly, these analyses were 
independent of inflammatory cell infiltration and are therefore unlikely to be 




Figure 11. Evidence for activation of mitophagy in WAT of obese mice.  
Immunoblot analysis of markers of mitophagy and autophagy: (A) Western blots 
of Parkin and Pink 1 in adipose tissues from mice fed a LFD or HFD for 6 weeks 
(left panels) or 12 weeks (right panels); and (B) Quantification of Parkin and 
Pink1 abundance from panel E. n = 4 per group; *p<0.05 vs. LFD. n = 4 per 
group; *p<0.05 vs. 6 wk LFD, #p<0.05 vs 12 wk LFD. (C) Representative Western 
blots of ubiquitinated proteins, p62, and LC3 in mice fed a LFD or HFD for 6 
weeks.  (D) Quantification of protein-ubiquitin abundance. (E) Quantification of 
p62 abundance. (F) Quantification of LC3-I abundance. (G) Quantification of 
LC3-II abundance. (H) Quantification of the LC3-II/LC3-I ratio.  n = 10 per group; 









dataset also indicated possible changes in energy metabolism. The Krebs cycle 
intermediate, succinate, was significantly elevated in adipose tissue from obese 
mice.  Further experiments identified early decreases in citrate synthase activity 
and explant oxygen consumption that coincided with decreased expression of 
pgc1a; yet diminishment in citrate synthase activity was independent of 
decreases in mitochondrial abundance, as indicated by mtDNA measurements 
and the abundance of electron transport chain subunits. Evidence of 
mitochondrial remodeling was found with 6 weeks of HFD, and elevation of the 
mitophagy markers Parkin and Pink1 persisted through 12 weeks of feeding. The 
decrease in p62 and LC3-I and elevation of the LC3-II/LC-I ratio in WAT from 
obese mice support the notion that  autophagic flux is increased in adipocytes of 
mice fed a high-fat diet. Collectively, these studies suggest a progressive 
remodeling of adipocyte metabolism under conditions of nutrient excess that 
involves downregulation of mediators of mitochondrial biogenesis, mitochondrial 
remodeling, and potential activation of the mitophagic program.   
 A major goal of this study was to understand changes in adipose tissue 
biology and metabolism that occur with obesity.  This is important because such 
key metabolic features that change with obesity could become targets for anti-
obesity or insulin-sensitizing therapies. By 6 weeks of HFD, mice demonstrate 
profoundly increased fat mass, decreased systemic VO2, VCO2 and RER, and 
insulin resistance.  Although adipose tissue inflammation is apparent by the 10th-
12th week of HFD in this model 294, 295, 6 weeks of HFD was insufficient to 




155, 295).  In addition, no increase in plasma levels of sensitive markers of 
inflammation such as IL-6 were identified at 6 weeks of HFD (IL-6 (pg/ml): LFD, 
23.6±7.5; HFD, 18.8±4.2).  The absence of significant levels of inflammation 
therefore allowed us to examine how obesogenic changes due to HFD regulate 
adipose tissue metabolism without the confounding features of highly energetic 
infiltrating cells such as macrophages 296.   
Metabolomic analyses showed several metabolic pathways affected in 
obesity.  These include glycerolipid metabolism, amino acid metabolism, and 
energy and glucose metabolism.  HFD decreased levels of long-chain fatty acids 
in adipose tissue, and, coupled with significant decreases in glycerol and 1-
palmitoylglycerol, is consistent with an increase in lipogenesis.  
Glycerophosphoethanolamine (GPEA), one of the few metabolites that increased 
in adipose tissue from obese mice, could be elevated as a result of 
phosphatidylethanolamine (PE) breakdown. This is consistent with the decreased 
abundance of 1-palmitoleoylglycerophosphoethanolamine and lysoPE species in 
adipose tissue from HF-fed mice. Increased GPEA could also be due to 
limitations in the rate of its hydrolysis: GPEA can be hydrolyzed by enzymes 
such as glycerophosphodiester phosphodiesterase to form glycerol-3-phosphate 
(G3P) 297, which is required for the formation of triglycerides and thus would likely 
be in high demand in expanding adipocytes 298.   
Demand for G3P may also be met by glycolysis and glyceroneogenesis, 




study, G3P was significantly decreased, suggesting that it might be used quickly 
to accommodate lipid storage.  The glycolytic intermediate glucose-6-phosphate 
was decreased as well, which suggests perturbations in adipocyte glucose 
metabolism.  Indeed, pdk4 expression, which regulates pyruvate dehydrogenase 
activity, was decreased by HFD; it is then plausible that the decrease in pdk4 
may promote the glyceroneogenic formation of G3P 299 via cataplerosis 300. The 
possibility that systemic glucose metabolism was affected by HFD is supported 
by the lower abundance of 1,5-anhydroglucitol in samples from mice fed a HFD. 
Plasma 1,5-anhydroglucitol (1,5-AG), is distributed to all organs and tissues and 
is a validated marker of short-term glycemic control 301, 302.  Hence, even though 
fasting glucose levels are not different after 6 weeks of HFD 286, the decrease in 
this metabolite is in agreement with insulin resistance in skeletal muscle and liver 
occurring at 6 weeks of HFD 155.   
The increase in stearoyl sphingomyelin in adipose tissue from mice fed a 
HFD may be particularly significant. Sphingomyelin (SM; d18:1/18:0)—which in 
humans is the only membrane phospholipid not derived from glycerol—is a type 
of sphingolipid found in cell membranes that consists of oleic acid attached to the 
C1 position and stearic acid attached to the C2 position. Deficiency of enzymes 
involved in sphingomyelin synthesis have been shown to protect against diet-
induced obesity and insulin resistance 303, 304, and the breakdown of 
sphingomyelin could yield significant amounts of ceramide, which inhibits insulin 
signaling 305.  Hence, the elevated levels of sphingomyelin could poise 




sphingomyelinases.  Although ceramides were not measured in these analyses, 
HFD has been shown to increase plasma and adipose ceramides in mice by 
more than 300% 306. Interestingly, depleting ceramides in mice fed a HFD 
increases oxygen consumption and citrate synthase activity as well as preserves 
PGC1 expression 307, 308, all of which were decreased by HFD in the current 
study.  Ceramide also alters membrane permeability, inhibits electron transport 
chain function and promotes oxidative stress 200, which is consistent with the 
evolving hypothesis that ceramide (and by proxy excess SM) induces 
mitochondrial stress 305.   
In addition to changes in lipid and glucose metabolism, metabolites in the 
amino acid and energy metabolism pathways were also remarkably changed by 
HFD.  Recent studies suggest that changes in amino acid metabolism may be 
critical to the development of obesity and insulin resistance.  In particular, 
pathway impact analyses showed that BCAA and phenyalanine, tyrosine, and 
tryptophan metabolism were significantly impacted by diet.  In obese and insulin-
resistant humans, these amino acids are elevated systemically (reviewed in 309), 
and changes in several amino acid classes, including BCAAs and Phe, Tyr and 
Trp, are associated with metabolic risk factors in humans 310.  Although there is a 
clear relationship among amino acids, insulin resistance and obesity in animal 
models, the mechanistic interpretations are less clear.  For example, increasing 
circulating BCAAs in mice by preventing BCAA catabolism prevents diet-induced 
obesity and insulin resistance in mice 311, whereas feeding BCAAs to high fat-fed 




appear to be important because BCAA metabolism in adipose tissues modulates 
levels of circulating BCAAs 313.  In our study, we found that several amino acids 
were decreased in abundance in adipose tissues from mice fed a HFD for 6 
weeks. This could be due to changes in the catabolic flux of BCAAs, which 
occurs in the mitochondrial matrix.   
While most studies show a decrease in BCAA catabolism in obesity 309, 
our data are most consistent with an increase in BCAA catabolism. BCAA 
catabolism results in the formation of acetyl CoA and succinyl CoA, the latter of 
which can be converted to succinate by hydrolysis and release of CoA by 
succinate thiokinase. Interestingly, succinate was one of the few metabolites that 
were significantly increased in WAT from HF-fed mice.  Other Krebs cycle 
intermediates, such as citrate and malate, were not changed in abundance.  This 
would appear to suggest an influx of carbon from BCAA catabolism into the 
Krebs cycle, which might be sufficient to sustain concentrations of other citric 
acid cycle intermediates or impart energetic changes.     
Interestingly, adipose explants derived from mice fed a HFD showed an 
apparent decrease in the rate of mitochondrial oxygen consumption; however, 
when the OCR rates were normalized to the wet weight of each explant the OCR 
was similar in adipose tissue from HF- and LF-fed mice. Given the fact that there 
was a 3-fold increase in adipocytes due to lipid accumulation, it is likely that the 
decreases in the apparent mitochondrial OCR are due simply to a decreased 




which comprises a large portion of the adipose tissue wet weight. Thus, despite 
extensive remodeling, mitochondrial function remains preserved. However, 
because the basal oxygen consumption in the explants was unaffected, it would 
suggest increased non-mitochondrial oxygen consumption potentially due to an 
increase in cytosolic oxidase activity 314, 315 in WAT from high-fat fed mice.  This 
possibility is consistent with  previous work showing an increase in adipose 
tissue oxidative stress in obsese mice, due to  an increase in the  expression of 
NADPH oxidase and downregulation of antioxidant enzymes 316-320.   
Despite no changes in mitochondrial number or oxygen consumption, 
there was a remarkable decrease in citrate synthase activity by HFD. This was 
accompanied by an increase in the gene expression of some subunits (e.g., 
cox7a1) in the adipose tissue of obese mice. These observations suggest that 
HFD promotes an early remodeling of mitochondria to accommodate for shifting 
metabolic needs and substrate availability. Reasons for increased cox7a1 gene 
expression and the augmented response of adipose explants from 6 week high 
fat-fed mice to FCCP are currently unclear. We speculate that the enhanced 
response to FCCP relative to the basal OCR could be due to increased substrate 
delivery to adipose tissue mitochondria in high fat-fed mice, which occurs only 
when the proton motive force is diminished with the uncoupler. Cox7a1, is a 
heart and muscle-specific subunit, which is also present in brown adipocytes. 
This subunit has been shown to be increased in the WAT of fattening cattle 321. 
While reasons for the increase in this subunit are not clear, it is possible that its 




adipocyte. Further studies are required to assess fully the role of this subunit in 
mediating energetic changes in WAT during obesity.   
With prolonged high fat feeding (i.e., 12 weeks), decreases in 
mitochondrial mass do appear to occur, which is supported both by our results 
showing decreases in mitochondrial matrix and inner membrane proteins as well 
as by published studies showing decreased mitochondrial mass in WAT of 
severely obese mice 161, 283 and humans 322. These data are consistent also with 
published data showing a decrease in adipocyte mitochondrial function in obese 
humans, independent of adipocyte size 322.  
Electron micrographs showed mitochondria appearing to undergo fission 
in adipose tissue from HF-fed mice, and autophagosomes were found adjacent 
to vacuolated structures containing electron-dense material and to mitochondria.  
This suggested that both mitochondrial remodeling and autophagy may be 
induced by HFD. That Parkin and Pink1 were also increased in adipose tissues 
from obese mice would support the notion that mitophagy is induced by HFD.  
Previous studies show that Pink1 accumulating within mitochondria recruits 
Parkin, which ubiquitinates mitochondrial proteins that are then recognized by 
autophagy adaptor proteins such as p62.  The p62 then binds to LC3 which 
sequesters mitochondria into autophagosomes for degradation 293. Although 
LC3-II and ubiquitinated proteins were not significantly changed with HFD, the 
abundance of p62 was decreased, which is consistent with an increase in 




both LC3-I and p62 have been shown to increase 324, 325, and, in our study, both 
p62 and LC3-I were decreased and the LC3-II/LC3-I ratio was increased.  These 
data would then be consistent with the notion that autophagy is increased in 
WAT of high fat-fed mice.  However, a limitation of this study is that autophagic 
flux was not measured. Nevertheless, the aggregate of ultrastructural and 
immunological data, combined with published data showing that autophagy is 
increased in adipocytes from obese humans and mice 326-328, suggest that HFD 
apparently increases autophagy and perhaps mitophagy in WAT. 
The loss of mitochondria shown to occur by the 12th week of HFD would 
then appear to suggest a role for autophagic degradation of mitochondria in the 
“whitening” of adipose tissue. Deletion of essential autophagy genes such as 
atg7 in mice results in resistance to obesity and promotion of a brown-like 
adipose tissue phenotype having more mitochondria and higher rates of 
substrate oxidation 325. Furthermore, mouse embryonic fibroblasts (MEFs) 
isolated from atg5−/− mice accumulate less lipid when stimulated to develop into 
adipocytes 325, suggesting that autophagy is essential for lipogenesis and WAT 
expansion. Interestingly, systemic knock-out of Parkin prevents diet-induced 
obesity and insulin resistance; however, this was shown to be due to decreased 
uptake of fat from the diet 329, indicating that functions of Parkin are not exclusive 
to mitophagy. Nevertheless, the Pink1-Parkin pathway has been shown to 
promote both mitophagy and selective respiratory chain turnover in vivo 330, 
which is consistent with our findings in adipose tissues of obese mice. The use of 




would further help to understand how mitophagy regulates adipose tissue 
phenotype.   
In summary, in this study we identified key metabolic changes that occur 
during WAT expansion. These coordinated changes occur before the infiltration 
of inflammatory cells and include: loss of mitochondrial biogenetic capacity; 
dysregulation of glycerolipid, sphingolipid and amino acid metabolism; 
mitochondrial remodeling; and changes suggestive of activation of mitophagy.  
Based on these observations, we posit that such metabolic remodeling 





OVEREXPRESSION OF ENDOTHELIAL NITRIC OXIDE S.NTHASE 




Obesity and type 2 diabetes (T2D) have become major health challenges 
worldwide. Current data show that approximately 1.5 billion adults aged 20 years 
or older are overweight, and 10% are obese 1. In the US, one-third of the 
population meets the criteria for metabolic syndrome 3, 4. While lifestyle changes 
and lack of exercise are important risk factors for weight gain 279, 331, excessive 
caloric intake appears to be one key factor fueling the epidemic of obesity. Poor 
dietary habits negatively affect a broad range of cardiovascular functions and 
promote the onset of T2D 4.  
Although it is currently believed that obesity results from excessive 
nutrient consumption 11, 332, i.e., more calories are ingested than are utilized, 
recent evidence suggests that the balance between nutrient intake and energy 
expenditure is complex and is regulated by many inter-dependent mechanisms 
332. Several studies indicate that obesity and insulin resistance may be distinct 
sequelae of nutrient excess 333. Hence, to stem the tide of the epidemics of
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 T2D and obesity, it is important to understand the relationship between obesity 
and insulin resistance as well as the physiological processes that regulate their 
development.   
Accumulating evidence suggests that the vascular endothelium regulates 
insulin action. In humans, states of obesity and insulin resistance are 
characterized by endothelial dysfunction, impaired vasodilation and insulin 
resistance 334; and in rats, inhibition of endothelial nitric oxide synthase (eNOS) 
decreases insulin-stimulated uptake of glucose by skeletal muscle, suggesting 
that eNOS may be a key regulator of metabolic homeostasis. This role of eNOS 
is further corroborated by observations that deletion of the eNOS gene in mice 
induces insulin resistance 335, 336 and impairs fatty acid oxidation 337. 
Nevertheless, the role of eNOS in regulating metabolic changes that contribute to 
obesity under conditions of nutrient excess is not well understood. In particular, it 
is unclear whether eNOS could prevent or attenuate diet-induced adiposity and 
insulin resistance. 
To understand the metabolic role of eNOS, we studied effects of high fat 
diet in mice overexpressing eNOS.  Our hypothesis was that increasing eNOS 
levels mitigates effects of high fat feeding by regulating adipose tissue 
metabolism.  We found that eNOS-transgenic (eNOS-TG) mice were resistant to 
diet-induced weight gain, but not glucose intolerance.  These findings reveal a 





Animal studies: The B6.BKS(D)-Leprdb/J (db/db) mice and C57BL/6J (wild-type; 
WT) mice were purchased from The Jackson Laboratory (Bar Harbor, ME).  The 
eNOS-TG mice, which express bovine eNOS under the control of the 
preproendothelin-1 promoter 338, were maintained on the C57BL/6J background.  
At 8 weeks of age, male mice were placed on either a 10% low fat diet (LFD; 
Research Diets, Inc., #D12450B) or a 60% high fat diet (HFD; Research Diets 
Inc., #D12492) and maintained for 6–15 additional weeks. Water and diet were 
provided ad libitum. Body weights were recorded weekly.  During the 7th and 13th 
weeks of feeding, glucose and insulin tolerance tests were performed. Pyruvate 
tolerance tests were performed only after the 13th week of feeding; all other 
variables were evaluated after euthanasia.  All procedures were approved by the 
University of Louisville Institutional Animal Care and Use Committee.  
 
Expression analyses: Tissue homogenates were prepared and used for 
Western blot protein expression analysis. For quantitative RT-PCR, RNA 
extracted from tissues was used to assess pgc1a, cytb6, gapdh, ppara, and 
pparg expression using commercially available primers (SABiosciences, 
Valencia, CA).   
 
Glucose, insulin, and pyruvate tolerance tests: As described before 339, 
glucose tolerance tests were performed following a 6 h fast by injection (i.p.) of 
80 
 
D-glucose (1 mg/g) in sterile saline. Insulin tolerance tests were performed on 
nonfasted animals by i.p. injection of 1.5 U/kg Humulin R (Eli Lilly, Indianapolis, 
IN). After a 6 h fast, pyruvate tolerance tests were performed as described 340.  
 
Biochemical analyses: Plasma lipids, proteins, and metabolites were measured 
using a Cobas Mira Plus 5600 Autoanalyzer (Roche, Indianapolis, IN) or Luminex 
kits (Millipore, Billerica, MA, USA).  Plasma levels of non-esterified free fatty 
acids and glycerol were measured by ELISA (Wako Chemicals, Richmond, VA 
and Cayman Chemical, Ann Arbor, MI, respectively). Nitrite and nitrate levels 
were measured as described 341. 
 
Adipocyte size measurements: Adipose tissue excised at the time of 
euthanasia was either snap-frozen at –80°C or fixed in 10% formalin (Leica), 
paraffin-embedded, and sectioned.  Sections were stained in hematoxylin and 
eosin. Adipocyte cross-sectional area was measured using Nikon Elements 
software. To assess relative mitochondrial abundance, sections were stained 
with MitoID Red (Enzo Life Sciences, Farmingdale, NY).  Crown-like structures 
and inflammatory cells indicative of adipose tissue inflammation were measured 




Body composition and calorimetry: Body composition was measured by dual-
energy X-ray absorptiometry using a mouse densitometer (PIXImus2; Lunar, 
Madison, WI). Whole body energy expenditure, respiratory exchange ratio, food 
consumption, and locomotion, ambulatory and fine movements were measured 
using a physiological/metabolic cage system (TSE PhenoMaster System, Bad 
Homberg, Germany).  
 
Immunostaining of adipose tissue: Capillary density was quantified in paraffin-
embedded sections using fluorescently labeled isolectin B4 as described 342. 
Nitrotyrosine adducts were measured in paraffin-embedded tissues using anti-
nitrotyrosine and goat-anti-rabbit IgG-Cy3 antibodies. 
 
Adipose tissue bioenergetic measurements: The oxygen consumption rate 
(OCR) and extracellular acidification rate (ECAR) of intact adipose tissue 
explants were measured using a Seahorse XF24 analyzer (Seahorse Bioscience, 
Billerica, MA). Briefly, freshly isolated epididymal adipose tissue was rinsed with 
unbuffered DMEM (Dulbecco’s modified Eagle’s medium, pH 7.4). The adipose 
tissue was cut into sections, and 10 mg were placed in each well of an XF 24 
Islet Capture Microplate (Seahorse Bioscience, Billerica, MA). The tissue was 
then covered with a screen, which allows free perfusion while minimizing tissue 
movement. Unbuffered DMEM (500 μl) supplemented with 50 μM BSA-
conjugated palmitic acid, 200 μM L-carnitine, and 2.5 mM D-glucose was then 
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added to each well. At least two replicates from each animal were used for the 
assay, and each tissue section was examined to ensure absence of large 
vessels (which can skew oxygen consumption measurements). The plate was 
incubated at 37°C in a non-CO2 incubator for 1 h prior to extracellular flux 
analysis. After three baseline measurements, a mixture of antimycin A (10 μM) 
and rotenone (1 μM) was injected.  Following injection, the OCR was closely 
monitored until the rates stabilized, and then the experiment was terminated.    
 
Metabolomic analysis of adipose tissue: White adipose tissue from the 
epididymal fat pad of fasted mice (16 h fast) was collected and snap-frozen in 
liquid nitrogen. At the time of analysis, sample metabolites were extracted with 
methanol.  A recovery standard was introduced at the beginning of the extraction 
process.  The extracted samples were split into equal parts for analysis on the 
GC/MS and LC/MS/MS platforms. Also included were several technical replicate 
samples created from a homogeneous pool containing a small amount of all 
study samples. Samples were placed briefly on a TurboVap® (Zymark) to remove 
the organic solvent. Each sample was then frozen and dried under vacuum.  
Samples were then prepared for the appropriate instrument, either LC/MS or 
GC/MS 
 
LC/MS, LC/MS2: The LC/MS portion of the platform was based on a Waters 
ACQUITY UPLC and a Thermo-Finnigan LTQ mass spectrometer, which 
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consisted of an electrospray ionization (ESI) source and linear ion-trap (LIT) 
mass analyzer. The sample extract was split into two aliquots, dried, then 
reconstituted in acidic or basic LC-compatible solvents, each of which contained 
11 or more injection standards at fixed concentrations. One aliquot was analyzed 
using acidic positive ion optimized conditions and the other using basic negative 
ion optimized conditions in two independent injections using separate dedicated 
columns. Extracts reconstituted in acidic conditions were gradient eluted using 
water and methanol both containing 0.1% formic acid, while the basic extracts, 
which also used water/methanol, contained 6.5 mM ammonium bicarbonate.  
The MS analysis alternated between MS and data-dependent MS2 scans using 
dynamic exclusion. 
 
GC/MS: Samples destined for GC/MS analysis were re-dried under vacuum 
desiccation for a minimum of 24 hours prior to being derivatized under dried 
nitrogen using bistrimethyl-silyl-triflouroacetamide. The GC column was 5% 
phenyl and the temperature ramp was from 40° to 300° C in a 16 minute period. 
Samples were analyzed on a Thermo-Finnigan Trace DSQ fast-scanning single-
quadrupole mass spectrometer using electron impact ionization. The instrument 
was tuned and calibrated for mass resolution and mass accuracy on a daily 
basis. The information output from the raw data files was automatically extracted 




Accurate mass determination and MS/MS fragmentation: In addition to the 
LIT front end, the LC/MS portion of the platform had a Fourier transform ion 
cyclotron resonance (FT-ICR) mass spectrometer backend. For ions with counts 
greater than 2 million, an accurate mass measurement could be 
performed. Accurate mass measurements could be made on the parent ion as 
well as fragments.  The typical mass error was less than 5 ppm. Fragmentation 
spectra (MS/MS) were typically generated in data-dependent manner, but if 
necessary, targeted MS/MS could be employed, such as in the case of lower 
level signals. 
 
QA/QC: Instrument variability was determined by calculating the median relative 
standard deviation (RSD) for the internal standards that were added to each 
sample prior to injection into the mass spectrometers. Overall process variability 
was determined by calculating the median RSD for all endogenous metabolites 
(i.e., non-instrument standards) present in 100% of the samples, which are 
technical replicates of pooled samples. Values for instrument and total process 
variability were 5% for internal standards and 15% for endogenous biochemicals, 
respectively. For QA/QC purposes, a number of additional samples are included 
with each day’s analysis. Furthermore, a selection of QC compounds was added 
to every sample, including those under test. These compounds were carefully 




Metabolite identification: Compounds were identified by comparison to library 
entries of purified standards or recurrent unknown entities.  Identification of 
known chemical entities was based on comparison to metabolomic library entries 
of purified standards. More than 1000 commercially available purified standard 
compounds had been acquired registered into the Metabolon Laboratory 
Information Management System (LIMS) for distribution to both the LC and GC 
platforms for determination of their analytical characteristics. The combination of 
chromatographic properties and mass spectra gave an indication of a match to 
the specific compound or an isobaric entity.   
 
Curation: A variety of curation procedures were carried out to ensure that a high 
quality data set was made available for statistical analysis and data 
interpretation. The QC and curation processes were designed to ensure accurate 
and consistent identification of true chemical entities, and to remove those 
representing system artifacts, mis-assignments, and background noise. 
Visualization and interpretation software were used to confirm the consistency of 
peak identification among the various samples. Library matches for each 
compound were checked for each sample and corrected if necessary. 
 
Bioinformatics: The bioinformatics system consisted of four major components, 
the LIMS system, data extraction and peak-identification software, data 
processing tools for QC and compound identification, and a collection of 
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information interpretation and visualization tools. The purpose of the LIMS 
system was to enable fully auditable laboratory automation through a secure, 
easy to use, and highly specialized system.  The scope of the LIMS system 
encompasses sample accessioning, sample preparation and instrumental 
analysis and reporting and advanced data analysis.  Some of the subsequent 
software systems were grounded in the LIMS data structures, which have been 
modified to leverage and interface with the Metabolon information extraction and 
data visualization systems, as well as other data analysis software such as 
Metaboanalyst (http://www.metaboanalyst.ca/). 
 
Metabolomic analysis: The general outline for how metabolomic data were 
analyzed is shown in Fig. 22. Metabolites with missing values were imputed by 
replacing missing values with half of the minimum positive value in the original 
data. Metabolites with greater than 57% of values missing were omitted from the 
analysis. Data were then quantile normalized within replicates after log 
transformation. This step was performed to transform the intensity values so that 
the distribution was more Gaussian. T-test statistical comparisons were then 
performed. Further univariate and multivariate analysis, such as correlation 
analysis, principal component analysis and partial least squares discriminant 
analysis was then performed using the Metaboanalyst 2.0 software 




Statistical analyses: Data are expressed as mean ± SEM. Multiple groups were 
compared using one-way or two-way ANOVA, followed by Bonferroni post-tests. 
Unpaired Student’s t test was used for direct comparisons. Statistical analyses 
were performed with the program “R” http://cran.r-project.org/, Metaboanalyst 
(http://www.metaboanalyst.ca/), and/or GraphPad 5.0.   A P value less than 0.05 
was considered significant. 
 
Results 
Nutrient excess alters eNOS abundance.  To study effects of obesity and 
diabetes on eNOS protein levels, C57BL/6J mice were placed on a high fat diet 
155, and db/db mice were used as a model of T2D 344. High fat feeding for 6 and 
12 weeks resulted in a profound decrease in eNOS levels in adipose tissue (Fig. 
12A,B), with no statistically significant changes in the aorta (Fig. 12A,C) or 
skeletal muscle (Fig. 13A,B). Similar changes were observed in 20 week old 
db/db mice, in which eNOS in the adipose tissue was undetectable despite a lack 
of change in eNOS levels in most other tissues. Interestingly, eNOS expression 
was increased in hearts of db/db mice (Fig. 13A,C), which might be a 
compensatory change in response to an increase in NO demand. These data 
show that both obesity and diabetes result in tissue-specific changes in eNOS 
expression with a profound and selective decrease in eNOS levels in the adipose 
tissue. This decrease in eNOS in adipose tissue is consistent with previous 
reports in obese humans 158, 159 and in mouse models of obesity 161, indicating 
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that the expansion of adipose tissue establishes a state of chronic eNOS 
deficiency.  
 
Overexpression of eNOS prevents diet-induced obesity.  To examine the role 
of eNOS, we used eNOS-TG mice 338. Previous studies have shown that these 
mice reproduce in a Mendelian fashion, maintain normal growth characteristics, 
and are protected from numerous pathologies including myocardial 345, hepatic 
346, lung 347, and vascular injury 348 as well as sepsis 349.  In comparison with WT 
mice, hemizygous mice showed a 4-fold increase in eNOS levels in the aorta, 
with no significant change in eNOS levels in the adipose tissue (Fig. 12D,E).  In 
contrast, in homozygous mice there was a 2-fold increase in eNOS in the 
adipose tissue and a 6-fold increase in the aorta. The eNOS in TG animals 
localized exclusively with isolectin staining (Fig. 14), indicating that the transgene 
was expressed only in the vasculature 338, 350.  Plasma from eNOS-TG mice 
showed increased L-citrulline and nitrite levels when compared with WT mice 
(Fig. 15A,C), and adipose tissue from eNOS-TG mice demonstrated an increase 
in L-citrulline (Fig. 15B). Due to high variability, there were no significant 
differences in nitrate or nitrite in adipose tissue (Fig. 15D) perhaps due to other 
confounding factors, such as nitrite/nitrate found in the diet or reduction of nitrite 
to NO.   
  When placed on a high fat diet for 6 weeks, the homozygous eNOS-TG 
mice gained 50% less weight than WT mice, and this effect persisted for 12 
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weeks (Fig. 16B,C). Food intake was not different between WT and eNOS-TG 
mice (Fig. 16D).  A more modest resistance to weight gain was also observed in 
hemizygous eNOS-TG mice (Fig. 13-D), perhaps due to lower adipose tissue 
eNOS levels in these mice compared with homozygous eNOS-TG mice. Hence, 
for all subsequent studies, only eNOS homozygous mice were used.  
The transgenic mice maintained a higher percent of lean mass (Fig. 16G), 
although the tibia length in transgenic mice was only slightly smaller than in WT 
mice (Fig. 16H). These observations indicate that overexpression of eNOS 
decreases adiposity and prevents weight gain induced by high fat diet. 
 
eNOS overexpression increases whole body metabolism.  To determine how 
eNOS overexpression affected whole-body metabolism, we measured oxygen 
consumption (VO2), carbon dioxide production (VCO2), and activity in high fat-fed 
WT and eNOS-TG mice over the course of a 12 h dark period and a 4.5 h light 
period. The fact that food intake was not different between WT and TG mice (Fig. 
16D), indicates that the lean phenotype of eNOS-TG mice is not due to a 
decrease in food consumption. This view is reinforced by the observation that 
high fat feeding increased plasma cholesterol and leptin to similar levels in WT 
and eNOS-TG mice (Table 2). In comparison with WT mice, eNOS-TG mice 
showed higher mean VO2 and VCO2 rates throughout the dark and light periods 
(Fig. 16I,J), with no change in the respiratory exchange ratio (RER; Fig. 16K).  
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Figure 12. Nutrient excess alters tissue eNOS levels. Tissue levels of eNOS 
from mice fed a low fat (LFD) or high fat diet (HFD) for 6 or 12 weeks; age-
matched db/db mice were included as an additional model of T2D: (A) 
Representative Western blots of eNOS from epididymal adipose tissue and 
aorta. (B,C) Quantification of eNOS expression from panel A. n = 3–4 per 
group;**p<0.01 vs. 6 week LFD. (D,E) Levels of eNOS in adipose tissue and 
aorta from wild-type (WT), littermate eNOS-TG hemizygous, and eNOS-TG 











Figure 13. Effects of nutrient excess on eNOS levels, and body weight gain 
of mice expressing different levels of eNOS. Panels A–C: Immunoblot 
analysis of eNOS expression in skeletal muscle and heart in C57BL/6J mice fed 
a low fat diet (LFD) or high fat diet (HFD) for 6 or 12 weeks; db/db mice age-
matched to the 12 week feeding group were included as an additional model of 
metabolic syndrome.  (A) Representative Western blots of eNOS expression in 
skeletal muscle and heart; (B) Quantification of skeletal muscle eNOS 
expression; and (C) Quantification of heart eNOS expression. n = 3–4 per 
group;***p<0.001 vs. WT LFD. Panel D: Weight gain of wild-type, littermate 
eNOS hemizygous, and eNOS homozygous mice fed HFD over the course of 12 








Figure 14. The eNOS transgene localizes to the vasculature in adipose 
tissue. Immunofluorescence images of epididymal adipose tissue from eNOS-
TG mice: Adipose tissues were fixed, sectioned, and stained with DAPI (blue), 
isolectin (green), and eNOS antibody (red).  The overlay shows the co-







Figure 15.  Measurements of eNOS and NO metabolites in plasma and 
adipose tissue. Mice were fed a LFD or HFD for 6 weeks and citrulline, nitrite, 
and nitrate levels in the plasma and adipose tissue were analyzed by LC/MS or 
HPLC.  Panels A and B: Relative levels of L-citrulline from (A) plasma and (B) 
adipose tissue; Panels C and D: Measurements of nitrite from (C) plasma and 
(D) adipose tissue; Panels E and F: Measurements of nitrate from (E) plasma 
and (F) adipose tissue. n = 6–7 per group; *p<0.05 vs. WT LFD;
 #
p<0.05 vs. TG 
LFD; 
$







Activity levels, assessed by horizontal activity count (beam breaks) 
showed similar patterns and levels of activity, and total ambulatory activity was 
not significantly different (Fig. 16L). Taken together, these observations suggest 
that on a high fat diet, eNOS-TG mice maintain a higher metabolic rate than WT 
mice. This increase in systemic metabolism, however, cannot be attributed to 
thyroid hormones, because plasma levels of triiodothyronine (T3) and thyroxine 
(T4) in WT and eNOS-TG mice were not significantly different (Fig. 17).  
Measurements of body composition by dual-energy X-ray absorptiometry 
(Dexascan) showed that after 6 weeks of high fat feeding, the body fat content 
was much lower in eNOS-TG mice than in non-transgenic mice (Fig. 16E,F).  
 
Effect of eNOS on diet-induced insulin resistance. Because we found that 
eNOS overexpression prevented diet-induced weight gain, we expected 
concurrent changes in insulin resistance. Indeed, we found that overexpression 
of eNOS completely prevented diet-induced hyperinsulinemia (Table 2), although 
plasma levels of adiponectin and resistin were not affected.  This was associated 
with a remarkably lower HOMA-IR score (WT low fat, 1.45±0.65; WT high fat, 
34.4±5.3, p<0.05 vs. WT low fat; TG low fat, 6.9±3.1; TG high fat, 8.2±2.9, 
p<0.05 vs. WT high fat). Moreover, even though 6 weeks of high fat feeding did 
not significantly increase triglycerides or plasma non-esterified free fatty acids 
(NEFA), both of these were decreased by 50% in the TG mice compared with 
WT mice (Table 2).  We found no significant differences in plasma glycerol 
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between groups (Table 2), suggesting that adipose tissue lipolysis was not 
affected. Collectively, these data indicate that overexpression of eNOS prevents 
high fat diet-induced hyperinsulinemia and decreases plasma triglycerides and 
fatty acids.  
To examine how eNOS overexpression affects systemic glucose disposal, 
WT and eNOS-TG mice were placed on a high fat diet for 6 weeks, and GTT and 
ITT were performed. There was no significant difference in the basal blood 
glucose levels in non-fasted WT and eNOS-TG mice (Fig. 18A).  After a fast of 6 
h, the plasma glucose levels of both high fat-fed groups were significantly 
increased compared with the WT low fat-fed group. Fasting for 16 h resulted in 
near normalization of blood glucose in WT mice; however, glucose levels in the 
eNOS-TG mice remained slightly, but significantly, elevated (Fig. 18A).  There 
were no significant differences in plasma HbA1c in any group (Fig. 18B).  
To test whether effects of the transgene would manifest after prolonged 
feeding, we placed WT and eNOS-TG mice on high fat diet for 12 weeks and 
assessed insulin resistance. At completion of the feeding protocol, the GTT and 
ITT curves were superimposable suggesting that eNOS overexpression does not 
affect diet-induced insulin resistance even after prolonged nutrient excess (Fig. 
19A-D).  Although, plasma glucose levels in non-fasted and 6 h-fasted mice were 
not statistically different, a 16 h fast led to a greater decrease in blood glucose in 
WT compared with TG mice (Fig. 19E), indicating that the TG mice were more 
resistant to fasting-induced hypoglycemia, which could be due to increased 
gluconeogenesis in the liver.  
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Figure 16. eNOS prevents diet-induced obesity.  Weight gain, adiposity, and 
indirect calorimetry measurements from WT and eNOS-TG mice fed a low fat 
(LFD) or high fat diet (HFD): (A) Body weights during 6 weeks of LF feeding, n = 
22–26 per group; (B) body weights during 6 weeks of HF feeding, n = 26 per 
group; (C) summarized weight gain over the course of 6 weeks and 12 weeks of 
HF feeding, n = 28–29 per group for 6 week group, n = 4–7 per group for 12 
week group; (D) food intake, n = 4 per group; (E) representative DexaScan 
images of mice fed a LFD or HFD for 6 weeks; (F) body fat percentage, n = 8–12 
per group; (G) lean mass percentage, n = 8–12 per group; and (H) tibia length for 
mice fed a LFD or HFD for 6 weeks, n = 8–12 per group; (I) average oxygen 
consumption (VO2); (J) average carbon dioxide production (VCO2); (K) 
respiratory exchange ratio (RER); and (L) ambulatory counts. n = 4 per group; 









Figure 17. Diet and genotype do not affect circulating free T3 or T4 levels. 
Free triiodothyronine (T3) and thyroxine (T4) were measured in plasma from WT 










To test this, we performed pyruvate tolerance tests, which did not show 
remarkable differences between WT and TG mice (Fig. 19F,G), indicating that 
resistance to hypoglycemia in TG mice may not be due to increased hepatic 
production of glucose. Collectively, these data suggest that eNOS 
overexpression does not significantly affect diet-induced insulin resistance or 
glucose intolerance, but maintains glucose homeostasis during starvation.  
 
Effect of eNOS on adipose tissue. Given our observations that obesity and 
diabetes were associated with a selective decrease of eNOS levels in adipose 
tissue and that eNOS-TG mice were resistant to diet-induced weight gain, we 
measured changes in adipocyte area and size in epididymal fat pads.  These 
measurements revealed that high fat diet induced adipocyte hypertrophy leading 
to a 3–4-fold increase in mean adipocyte area (Fig. 20A,B).  Moreover, the high 
fat diet promoted size heterogeneity in WT, but not eNOS-TG mice (Fig. 20C), 
indicating that eNOS overexpression prevents diet-induced adipocyte 
hypertrophy and size dispersion. 
In murine models of diet-induced obesity, adipocyte hypertrophy is 
associated with inflammation and accumulation of macrophages in adipose 
tissue 351. This is commonly recognized by the presence of crown-like structures 
that appear between adipocytes 190, 287, 351. In humans, obesity is similarly 
associated with adipose tissue inflammation, and weight loss interventions such 
as bariatric surgery improve endothelial function 352, 353. 
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Figure 18. Effect of eNOS overexpression on indices of insulin resistance.  
After 6 weeks of a low fat (LFD) or high fat diet (HFD), glucose tolerance and 
insulin sensitivity were examined in WT and eNOS-TG mice: (A) Non-fasting and 
fasting glucose levels; white bars, WT LFD; blue bars, eNOS-TG LFD; white 
hatched bars, WT HFD; blue hatched bars, eNOS-TG HFD; (B) HbA1c; (C–E) 
glucose tolerance tests; and (F–H) insulin tolerance tests. n = 14 per group; 









Figure 19. Measures of insulin resistance and gluconeogenesis in WT and 
eNOS-TG mice fed a high fat diet for 12 weeks. After 12 weeks of HFD, 
glucose tolerance and insulin sensitivity were examined in WT and eNOS-TG 
mice: (A) Glucose tolerance test (GTT); (B) Insulin tolerance test (ITT); (C) GTT 
area under the curve (AUC); (D) ITT AUC; (E) Blood glucose under non-fasted, 
6-h-fasted and 16-h-fasted conditions; (F) Pyruvate tolerance test (PTT) was 
used to determine differences in gluconeogenesis between the mice; and (G) 
PTT AUC. n = 4 per group;*p<0.05 vs. WT. 






Therefore, we examined adipose tissue inflammation in WT and eNOS-TG mice 
after 6 weeks of high fat diet. Analysis of adipose tissue showed no significant 
difference in the abundance of crown-like structures between WT and TG mice 
(Fig. 20A), and analysis of the adipose tissue stromal vascular fractions showed 
no difference in total F480+ cells or changes in macrophage subtypes (Fig. 21).  
These results are in accordance with studies showing that macrophage 
accumulation and insulin resistance occur only with prolonged high fat feeding 
(>10 weeks)155, 295 and suggest that the anti-hypertrophic effects of eNOS are not 
associated with significant changes in adipose tissue inflammation, but are likely 
to be related to favorable changes in metabolism that prevent lipid accumulation 
and adipocyte expansion. 
 
Metabolic changes in adipose tissues of eNOS-overexpressing mice. The 
lean phenotype of eNOS-TG mice and their resistance to diet-induced weight 
gain and adipocyte expansion clearly indicated that eNOS overexpression has a 
significant impact on adipocyte metabolism. Therefore, to assess this impact, we 
measured metabolite levels in epididymal adipose tissue of high fat-fed WT and 
eNOS-TG mice using UHPLC/MS/MS and GC/MS. Spectral data were identified, 
searched against a standard library, and quantified (Fig. 22).  Internal standards, 
including injection standards, process standards, and alignment standards were 
used for quality control and to control for experimental and instrument variability. 
This analysis led to the identification of 192 metabolites of which 37 were 
significantly different between WT and eNOS-TG mice (Fig. 23A and Table 3). 
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Figure 20. eNOS overexpression decreases diet-induced adipocyte 
hypertrophy. Adipocyte size measurements from WT and eNOS-TG mice fed a 
LFD or HFD for 6 weeks: (A) Representative hematoxylin and eosin-stained 
images  of adipose tissue from the epididymal fat pad (×20 magnification; scale 
bar = 100 μm); (B) Mean adipocyte area; (C) Distribution of adipocyte sizes from 
mice fed a LFD (upper panel) and a HFD (lower panel). n = 5 per group, *p<0.05 








Figure 21. Effects of high fat diet on macrophage subtypes in WT and 
eNOS-TG mice. Macrophage subpopulations measured in epididymal adipose 
tissues after 6 weeks of LFD or HFD: (A–D) Representative flow cytometry dot 
plots of F4/80
+
 adipose tissue macrophages from WT and eNOS-TG mice. (E) 
Quantification of M1 macrophage subpopulations; (F) Quantification of M2 
macrophage subpopulations; and (G) Quantification of macrophages doubly 








Figure 22. Flow chart illustrating procedure for metabolomic profiling of 
adipose tissues.  Mice were fed a HFD for 6 weeks.  The adipose tissue was 
then procured, and metabolites were extracted.  The samples were divided for 
GC/MS or LC/MS analysis.  Following spectral analysis, the data were imputed, 
normalized, and analyzed using Metaboanalyst 2.0 software.  









Although intermediates in the glycolytic pathway and TCA cycle were not 
affected, there were significant increases in propionylcarnitine, acetylcarnitine, 3-
dehydrocarnitine, and isobutyrylcarnitine, some of which have been shown to 
stimulate fatty acid oxidation 354, 355. Higher levels of amino acids such as 
threonine, methionine, valine, isoleucine, and leucine were also observed in TG 
mice (Table 3). Multivariate and cluster analyses showed that these changes 
were determining factors in the separation of the groups (Fig. 23B,C), and 
pathway impact analysis (Fig. 23D) suggested that changes in amino acid 
synthesis and degradation may be important features regulating the lean 
phenotype of eNOS-TG mice. Plotting of the z-scores of metabolites from 
adipose tissues of eNOS-TG and WT mice showed increases in short-chain 
acylcarnitines as well as amino acids and their degradation products (Fig. 24A). 
Metabolites correlating with citrulline levels showed a similar pattern of 
metabolites (Fig. 24B). The adipose tissue metabolites in eNOS-TG mice shown 
to be significantly different from WT mice equated to differences in urea 
cycle/arginine metabolism, branched chain amino acid (BCAA) metabolism, 
carnitine metabolism, purine metabolism, oxidative phosphorylation, and fatty 
acid metabolism subpathways (Fig. 24C). Taken together, changes in metabolite 
levels in the adipose tissue indicated that overexpression of eNOS stimulates 
amino acid and fatty acid metabolism in adipose tissue.  
Adipose tissue mitochondria are increased in eNOS-TG mice. Favorable 
changes in BCAA and fatty acid metabolism are indicative of increased 
mitochondrial activity. Previous studies have shown that BCAA increases 
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mitochondrial biogenesis and that this is attenuated in eNOS-null mice 356. In 
addition, it has been reported that NO triggers mitochondrial biogenesis in 
adipocytes and that deletion of eNOS decreases mitochondrial content in 
adipose tissue 357. Based on this evidence, we hypothesized that the change in 
BCAA and fatty acid metabolism in the adipose tissue of eNOS-TG mice may be 
related to greater mitochondrial content. Indeed, adipose tissue, but not skeletal 
muscle, from eNOS-TG mice showed significant increases in key mitochondrial 
proteins such as COX4I1 and ALDH2 (Fig. 25A,C).  The increase in 
mitochondrial proteins in TG adipose tissue could be due to remodeling of the 
mitochondria or an increase in mitochondrial abundance. To distinguish between 
these possibilities, sections of adipose tissue were stained with a non-membrane 
potential-dependent mitochondrial stain, mitoID-Red.  As shown in Fig. 25E, 
adipose tissue isolated from high-fat-fed eNOS-TG mice stained more strongly 
than WT mice, indicating that the adipose tissue mitochondrial content was 
higher in TG than WT mice. Indeed, adipocytes isolated from high fat-fed eNOS-
TG mice were more brown in color than those isolated from WT mice (Fig. 25F), 
suggesting an increase in mitochondrial cytochromes. Indeed, in addition to 
increased abundance of COX4I1 (Fig. 25A,C), the expression of the 
mitochondrial gene cytochrome b6 (cytb6), was elevated 2-fold in eNOS-TG mice 
(cytb6:gapdh ratios, fold change: WT, 1.0±0.1; eNOS-TG, 2.0±0.3; n=4–7/group, 
p<0.05).  That this increase in mitochondrial content may be due to increased 
biogenesis is supported by our observation that in comparison with WT mice, TG 
mice had higher adipose levels of PGC1α and Sirt3, as well as an increase in  
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Figure 23. Metabolomic analyses of adipose tissues from high fat-fed mice.  
Metabolomic analyses of epididymal adipose tissue metabolites from WT and 
eNOS-TG mice fed HFD for 6 weeks: (A) Univariate analysis: t-tests of 
compounds from adipose tissues. All metabolites above the dotted line were 
found to be significantly different between WT and eNOS-TG mice (p<0.05).  
Each of these metabolites is listed in Table 4; (B) Multivariate analysis: partial 
least squares-discriminant analysis (PLS-DA); (C) Hierarchial clustering: 
Heatmap and dendogram using the the most significantly different metabolites. 
(D) The significant metabolites were subjected to pathway impact analysis using 
Metaboanalyst MetPA and the Mus musculus pathway library. Fisher’s exact test 
was used for overrepresentation analysis, and relative betweenness centrality 










Figure 24. Overexpression of eNOS regulates intermediary metabolism in 
adipose tissue.  Metabolite analysis from adipose tissues of WT and eNOS-TG 
mice fed HFD for 6 weeks: (A) z-score plots of significantly changed metabolites; 
(B) Correlation analysis was assessed using the Spearman rank correlation test, 
and metabolites that correlated with citrulline were then examined. (C) Super- 
and sub-pathway distribution of adipose tissue metabolites found to be 
significantly different between WT and eNOS-TG mice. n=14 animals: 7 WT HFD 








ppar and   (Fig. 25G); factors that are important activators of mitochondrial 
biogenesis 284, 358-362.  
 
Effect of eNOS on adipose tissue metabolic flux. To assess the functional 
implications of our observations, we measured oxygen consumption in adipose 
tissue explants using extracellular flux technology. As shown in Fig. 26B, adipose 
tissue from eNOS-TG mice showed a significantly higher oxygen consumption 
rate (OCR) compared with adipose tissue from WT mice. To determine the 
contribution of mitochondria to the OCR, we treated explants with the electron 
transport chain inhibitors antimycin A and rotenone. The stabilized rate measured 
thereafter was used to calculate the mitochondria-derived OCR, which was 2-fold 
higher in eNOS-TG compared with WT adipose tissue (Fig. 26C).  No statistically 
significant difference was observed in the extracellular acidification rate (ECAR), 
a surrogate index of glycolysis (Fig. 26D). Collectively, these observations 
corroborate our metabolic, biochemical, and anatomical measurements by 
demonstrating directly that the adipose tissue of eNOS-TG mice maintains a 
hypermetabolic state that could at least partially account for their increase in 
whole-body oxygen consumption and resistance to obesity.  
 
Discussion 
The major findings of this study are that high fat diet results in the 
downregulation of eNOS in adipose tissue and that overexpression of eNOS 
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Figure 25. Mitochondria are increased in the adipose tissue of eNOS-TG 
mice.  Measurements of mitochondria in epididymal adipose tissue and skeletal 
muscle from WT and eNOS-TG mice: (A) Representative Western blots of 
adipose tissue eNOS, PGC1α, ALDH2, COX4I1, and Sirt3; GAPDH was used as 
a loading control. (B) Representative Western blots of skeletal muscle eNOS, 
PGC1α, VDAC, COX4I1, and Sirt3. GAPDH was used as a loading control.  (C) 
Quantification of protein expression from panel A. (D) Quantification of protein 
expression from panel B. n = 3 per group; *p<0.05 vs. WT; White bars, WT; blue 
bars, TG. (E) Immunofluorescence images of adipose tissue sections from HF-
fed WT (panel i) and eNOS-TG (panel ii) mice; the sections were stained with 
MitoID-Red as a qualitative index of mitochondrial mass. Scale bar=200 μM  (F) 
Representative photomicrograph of adipocytes isolated from HF-fed WT and 
eNOS-TG mice (600,000 adipocytes per well). (G) mRNA analysis of Ppara and 
Pparg. White bars, WT LFD; blue bars, eNOS-TG LFD; white hatched bars, WT 










Figure 26. eNOS overexpression increases adipose tissue mitochondrial 
energetics. Extracellular flux (XF) analysis of adipose tissue explants from WT 
and eNOS-TG mice fed a HFD for 14 wks: (A) Representative photomicrographs 
of adipose tissue explants used for XF analysis; (B) Oxygen consumption rates 
(OCR) of adipose tissue explants:  After three baseline measurements, antimycin 
A and rotenone (AA/Rot) were injected to identify the mitochondria-dependent 
OCR. (C) Mitochondrial OCR calculated from measurements in panel B. (D) 
Extracellular acidification rate (ECAR) measured from adipose explants; ECAR is 







prevents diet-induced obesity.  These findings support a causal role of eNOS in 
regulating obesity and whole-body metabolism.  Our results suggest that the 
mechanism of this anti-obesogenic effect of eNOS is related to an increase in 
whole-body oxygen consumption associated with increased mitochondrial 
abundance and activity in the adipose tissue. Collectively, these observations 
support the notion that NO is an important regulator of adipocyte metabolism and 
thereby weight gain due to a high fat diet.  While it has been shown before that 
deletion of eNOS gives rise to features of metabolic syndrome 336, the rescue of 
the obese phenotype by increasing eNOS indicates that enhancing eNOS 
expression can overcome the metabolic changes caused by consumption of high 
fat diet. 
Several lines of evidence gathered during this study support the view that 
the anti-obesogenic effects of eNOS are due to favorable changes in adipocyte 
metabolism. Although on the basis of current results we cannot rule out, or even 
fully assess all potential systemic effects, our observations that food 
consumption, activity, plasma levels of cholesterol, leptin and thyroid hormones 
were not different between WT and TG mice argue against a global, systemic 
change that could completely account for the lean phenotype of the TG mice.  
Both insulin resistance and obesity are complex phenotypes that are regulated 
by multiple interactions between several tissues, some or all of which might be 
affected in a manner not captured by our current analysis.  Nevertheless, in 
regulating obesity, the adipose tissue appears to be a major target of eNOS. Our 
gene-dosage studies show that despite a 4-fold increase in eNOS in the aorta, 
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diet-induced obesity was only marginally affected in eNOS hemizygous mice, in 
which there was no increase in eNOS in adipose tissue. Only in homozygous 
mice, in which eNOS was increased both in adipose tissue and aorta, did the 
anti-obesogenic effects of eNOS become apparent. This association of the lean 
phenotype with eNOS expression in adipose tissue supports the view that an 
increase in NO in adipose depots may be required for the manifestation of the 
anti-obesogenic effects of eNOS. 
How does eNOS regulate adipose tissue metabolism? Our results suggest 
that eNOS supports both mitochondrial biogenesis and metabolic activity. 
Previous observations showing that β-oxidation is impaired in eNOS-null mice 337 
and that dietary supplementation with the NO precursor nitrite reverses features 
of metabolic syndrome in eNOS-null mice 363 are supportive of this concept. 
Although AMP kinase (AMPK) has been shown to relate with NO levels 364, 365, 
we did not find an increase in the phosphorylation state of AMPK in adipose 
tissue (Fig. 27). However, we did find elevated levels of several metabolites such 
as BCAAs and short-chain acylcarnitines (e.g., acetylcarnitine, 
proprionylcarnitine) in the adipose tissue of TG mice that were indicative of high 
metabolic activity. Interestingly, oral supplementation with proprionylcarnitine 
reduces obesity and hyperinsulinemia in obese rats 366, which at least partially 
recapitulates the phenotype of eNOS-TG mice. We also found in the adipose 
tissue of TG mice elevated levels of proteins such PGC-1α and Sirt3 and 
increased expression of ppara and pparg that regulate mitochondrial activity, 
fatty acid oxidation, and biogenesis 284, 358-362, 367, 368. That the increase in these
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Figure 27.  Western blot analysis of AMPK activation status. Mice were fed a 
LFD or HFD for 6 weeks and P-AMPK and total AMPK abundance were 
measured by western blotting. n = 3–4 per group 






proteins was functionally significant is reflected by our observations that 
mitochondrial abundance and rates of fatty acid oxidation were higher in the 
adipose tissue from eNOS-TG mice.  On the basis of these observations, we 
propose that high levels of eNOS lead to an increase in mitochondrial biogenesis 
and stimulation of fatty acid oxidation. This establishes a state of heightened 
metabolism that attenuates the obesogenic effects of high fat consumption. 
  Although our results show that eNOS overexpression increases adipose 
tissue metabolism by increasing mitochondrial content and activity, metabolic 
activity could also be affected by eNOS-dependent changes in oxygen 
distribution. Hence, it is possible that adipocytes of eNOS-TG mice are better 
perfused than those of WT mice. Such an increase in tissue perfusion could be 
due to either regulatory effects on vascular tone 369 and O2 consumption370 or an 
increase in angiogenesis 371. Nevertheless, we found that capillary density was 
unaffected by eNOS overexpression, as isolectin B4 staining per adipocyte and 
VEGFR2 expression were similar between the groups (Fig. 28), suggesting that 
an increase in angiogenesis is unlikely explain the lean phenotype of eNOS-TG 
mice. 
The metabolic role of eNOS, however, appears to be tissue-specific.  We 
found that high fat feeding decreased eNOS in the adipose tissue but not in the 
heart or the skeletal muscle. Hence, we expected that overexpression of eNOS 
would ameliorate adipose tissue hypertrophy without affecting high fat-induced 
changes in other peripheral tissues. Data from eNOS-TG mice substantiated this 
expectation. These results showed that high fat-induced changes in glucose
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Figure 28. Overexpression of eNOS does not affect capillary density in 
adipose tissue. Fluorescence images and markers of capillary density in 
sections of epididymal adipose tissue isolated from WT or eNOS-TG mice fed a 
LFD or HFD for 6 weeks: (A) Representative images of isolectin B4 (green) 
staining. (B) Isolectin B4 staining quantified per adipocyte. n = 9 per group. (C) 
VEGFR2 expression in adipose tissue. Density of the VEGFR2 bands were 
normalized to amido black stain. n = 6 per group. Note: the apparent decrease in 
isolectin staining in HFD groups from panel A relates to an increase in adipocyte 
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disposal were not different between WT and eNOS-TG mice indicating that whole 
body glucose metabolism, which is regulated primarily by glucose uptake by the 
skeletal muscle 372, was not related to changes in eNOS levels. Nevertheless, the 
observation that despite their lean phenotype the TG mice develop insulin 
resistance is significant because a lean phenotype characterized by the browning 
of fat is usually associated with improved glucose tolerance 325, 373-375. It is likely 
that a decrease in eNOS is a critical event in adipose tissue but not skeletal 
muscle, and therefore, elevated levels of eNOS in the adipose tissue prevent 
obesity without affecting systemic insulin resistance.    
Results showing that overexpression of eNOS prevents obesity without 
affecting insulin resistance also suggest that the two symptoms of metabolic 
syndrome could be dissociated from one another. Similar segregation between 
obesity and insulin resistance has been described previously. For instance, it has 
been shown that overexpression of adiponectin completely rescues the diabetic 
phenotype of ob/ob mice while promoting morbid obesity 376. Moreover, the 
observations that decreasing inflammation 377-379 does not result in lower 
adiposity but improves insulin sensitivity, and that PPAR agonists decrease 
insulin resistance but increase weight gain 333 provide additional support that 
obesity and diabetes are disconnected and, in some cases, even conflicting 
events in the etiology of metabolic disease. However, it remains to be 
established how eNOS prevents hyperinsulinemia as well as impacts other 
processes that are associated with insulin resistance, such as inflammation. It is 
currently believed that, due to excessive adipocyte expansion, hypoxia and 
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necrosis occur in adipose tissue, which in turn leads to the recruitment of 
inflammatory cells 380, 381. The resultant low-grade chronic inflammation is 
proposed to establish a state of insulin resistance 382, 383. However, the eNOS-TG 
mice develop the anti-obesogenic phenotype far before macrophage infiltration, 
inflammation, and insulin resistance in adipose tissue occur 155, 295. 
It is important to note that the eNOS-TG mice did not display a 
lipodystrophic phenotype. Lipodystrophy in humans and animal models generally 
results in severe hypertriglyceridemia, hyperinsulinemia, and insulin resistance 
384-386. The eNOS-TG mice, however, show decreased triglycerides and were 
protected from hyperinsulinemia despite developing diet-induced glucose 
intolerance. The prevention of hyperinsulinemia does not appear to be due to a 
pancreatic defect: baseline insulin levels were not significantly different from WT 
mice (Table 2), the glucose tolerance test showed a normal profile (Fig. 18 and 
19), and the pancreatic islets from eNOS-TG mice appeared unremarkable (Fig. 
29). These observations raise the interesting possibility that hyperinsulinemia in 
response to systemic insulin resistance may be in part regulated by the adipose 
tissue, although additional work is required to fully understand this relationship.  
Additional investigations will also be required to assess how high fat diet 
affects eNOS activity and expression. Although it has been shown that eNOS 
levels are suppressed in high fat diet in part due to TNF--dependent 
mechanisms 161, the effects of diet on eNOS protein and activity are less clear. 
The eNOS protein is subject to several post-translational modifications including  
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Figure 29. Hematoxylin and eosin-stained images of pancreas from WT and 
eNOS-TG mice.  Representative photomicrographs of pancreas isolated from 
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phosphorylation 387, O-GlcNAcylation 388, S-glutathiolation 253, and acylation 389, 
390.  In addition, the enzyme could also be uncoupled and therefore generate 
superoxide instead of synthesizing NO. Interestingly, we found that while eNOS 
monomer abundance was maintained in eNOS-TG mice (Fig. 30), the 
phosphorylation of eNOS at Ser1177 and abundance of the eNOS dimer were 
significantly decreased in both WT and TG mice fed a high fat diet (Fig. 30). 
Although these changes in the eNOS-TG mice might be compensated by 
continually elevated levels of eNOS protein, as evidenced by persistently 
elevated citrulline levels (Fig. 15A,B), such changes in WT mice might result in a 
chronic state of NO deficiency. Moreover, uncoupling of the enzyme could lead to 
increased superoxide production and the formation of the toxic metabolite 
peroxynitrite. Indeed, we found increased nitrotyrosine formation in adipose 
tissue of high fat-fed mice (Fig. 31), although this was not significantly affected by 
eNOS overexpression.  Hence, in future studies it will be important to identify the 
processes that regulate eNOS activity and how they might be involved in the 
development of diet-induced obesity and insulin resistance. 
In conclusion, the present study shows that preventing eNOS depletion by 
forced expression of the eNOS transgene attenuates diet-induced obesity in 
mice, without ameliorating systemic insulin resistance.  These findings reveal a 
novel anti-obesogenic role of eNOS and are consistent with the notion that eNOS 
prevents weight gain in high fat-fed mice by stimulating mitochondrial biogenesis 
and activity in adipose tissues.  Further understanding of this role of eNOS could  
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Figure 30.  Analysis of eNOS expression and modification. Immunoblotting of 
eNOS enzyme states that reflect eNOS activity state: WT and eNOS-TG (TG) 
mice were fed a LFD or HFD for 6 weeks and eNOS abundance and 
phosphorylation status were examined by immunoblotting.  (A) Representative 
Western blots of eNOS dimer, Ser
1177
 phosphorylation of eNOS (P-eNOS), and 
the eNOS monomer; (B) Quantification of P-eNOS; (C) Quantification of the 
eNOS dimer; n = 3–4 per group; *p<0.05 vs WT LFD; 
#
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Figure 31. High fat feeding increases protein-nitrotyrosine adducts in 
adipose tissue.  Immunofluorescence images and quantification of nitrotyrosine 
adducts in adipose tissue: WT and eNOS-TG mice were fed a LFD or HFD for 6 
weeks. The adipose tissue was stained for nitrotyrosine adducts, and the adducts 
were visualized by fluorescence microscopy. (A) Negative (–) and positive (+) 
controls for nitrotyrosine staining. (B) Representative images of nitrotyrosine 
staining in WT and eNOS-TG mice fed a LFD or HFD. (C) Quantification of 
nitrotyrosine adducts from adipose tissues.  n = 3 per group; *p<0.05 vs. 
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lead to the development of new therapeutic modalities for preventing obesity and 








REGULATION OF S.STEMIC METABOLISM B. NITRIC OXIDE 
 
Introduction 
Our previous work shows that overexpression of eNOS in mice regulates 
diet-induced obesity, in part by increasing total body energy expenditure. This 
resistance to obesity in eNOS transgenic mice is associated with the presence of 
a more “brown-like” adipocyte in white adipose tissue depots, suggesting that 
eNOS-induced changes in adipose tissue could underlie the anti-obesogenic 
effects of eNOS. However, in rodents, adipocytes utilize less energy compared to 
other peripheral tissues such as liver and skeletal muscle, which have estimated 
metabolic rates 50 and 3 times that of adipose tissue, respectively 391, and they 
collectively account for at least 50% of the overall oxygen use 392. To understand 
the role of eNOS in regulating adipose tissue energy consumption and systemic 
energy expenditure, we estimated the proportion of whole body oxygen 
consumption that could be ascribed to adipose tissue.  
To estimate the contribution of adipose tissue consumption, whole body 
VO2 values and adipose tissue oxygen consumption rates were measured. Using 
the Ideal Gas Law: (pV = nRT), where p is pressure of the gas, V is volume of the
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gas, n is number of moles of the gas, R is the universal gas constant, and T is 
temperature in Kelvin, the number of moles of O2 consumed was calculated. The 
VO2 in wild type (WT) mice was 6.622 L O2/h/kg (Chapter III, Fig. 16I).  Assuming 
an average body weight of ~40 g per mouse, this corresponds to 0.26 L 
O2/h/mouse, which is equivalent to  250 mmols O2/day/mouse. Body fat 
percentage, as measured by dual X-ray absorptiometry, was approximately 30% 
(12.03 g fat) in the high fat-fed WT mice (Chapter III, Fig 16F). From adipose 
tissue explant respirometry, we calculated the mitochondrial oxygen consumption 
rate of adipose tissue explants from WT high fat-fed mice to be 21.94 pmols 
O2/min/mg tissue (Chapter III, Fig 26C). Therefore, 12,030 mg of adipose tissue 
consuming oxygen at a rate of 21.94 pmol/min/mg tissue is approximately equal 
to 263,938.2 pmols O2/min and 0.380 mmols O2/day. Thus, dividing the adipose 
explant value (0.380 mmols O2/day) by the whole body value (250 mmols 
O2/day/mouse) suggests that approximately 0.15% of the total O2 consumption 
per day is accounted for by adipose tissue in a WT mouse. When the same 
calculation was applied to eNOS-TG mice, 0.18% of oxygen consumption is 
attributed to adipose tissue; a difference of only 0.03% compared with WT mice.  
These estimates suggest that an increase in adipose tissue mitochondrial 
activity is unlikely to account for the anti-obesogenic phenotype of eNOS-TG 
mice. The differences in standard metabolic rate between animals of different 
body mass have been assessed to be due to proportional changes in the whole 
of energy metabolism 393. It has been estimated that ~90% of mammalian oxygen 
consumption in the standard state is due to mitochondrial activity of which ~80% 
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is coupled to ATP synthesis 393. Therefore, to assess the source of increased 
energy expenditure in eNOS-TG mice a wider metabolic analysis is necessary.  
The metabolic effects of nutrient excess extend beyond adipose tissue.  
Indeed, the skeletal muscle of obese diabetic patients is characterized by fewer 
and smaller-sized mitochondria 394, 395, with decreased oxidative capacity 396. 
Moreover, high fat diet decreases the expression of genes involved in oxidative 
phosphorylation and mitochondrial biogenesis of humans and mice 397. In the 
liver, it is associated with increased intracellular lipid accumulation 398-400. 
Mitochondrial abnormalities including ultrastructural lesions, depletion of mtDNA, 
decreased activity of respiratory chain complexes 401 and impaired mitochondrial 
β-oxidation have been found in patients with elevated hepatic lipid deposition 395, 
402, while increased expression or activity of hepatic fatty acid oxidation enzymes 
reduces fat accumulation 403-406.  
Metabolic dysfunction in peripheral tissue is likely to be reflected in the 
plasma. Dysregulated fatty acid oxidation is characterized by increased plasma 
levels of acylcarnitines in both obese and diabetic individuals 407 as well as in 
animal models of obesity and diabetes 408. Similarly, plasma lactate levels are 
increased in individuals with severe diabetes 409 and levels of circulating FFAs 
have been shown to be correlated with obesity and diabetes 410-412.  As a result, 
metabolic changes in tissues other that the adipose depots could strongly 
influence adiposity and thereby contribute to the metabolic phenotype of eNOS-
TG mice. Hence, identifying the specific metabolic pathways affected is therefore 
important understanding the mechanism(s) by which eNOS prevents obesity. 
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Recent advances in metabolomics have been critical for understanding 
the systemic effects of metabolic diseases like obesity and diabetes 413. By 
measuring and, in some cases, mathematically modelling, changes in 
metabolites found in biological fluids and tissues, metabolomic data can provide 
key information on metabolic changes required to link phenotype to genetics 414, 
415. In particular, biological fluids such as plasma and urine can be used to 
identify metabolic pathways that are perturbed by disease or impacted by drug 
treatment or experimental intervention 416-419. Interestingly, the idea of quantifying 
changes in biological fluids as markers of disease is not a new one.  Indeed, 
there is evidence of such endeavors occurring as early as ancient Greece and 
diagnostic 'urine charts' that linked the colors, smells and tastes of urine to 
various medical conditions were widely used from the Middle Ages onwards 414. 
Metabonomics, and the related field of metabolomics, uses modern techniques to 
analyse samples, but the basic principle of relating chemical patterns to biology 
is the same. More recently, highly sensitive analytical techniques (i.e., mass 
spectrometry, nuclear magnetic resonance spectroscopy) applied to 
metabolomics and systems biology have emerged at the forefront of drug 
discovery and understanding disease processes 420.  
Using a metabolomics approach, we examined plasma from WT and 
eNOS-TG mice fed low or high fat diets to identify changes in systemic 
metabolism caused by nutrient excess or eNOS overexpression. Our analysis, 
was driven by three main questions: 1) How are plasma metabolites affected 
by a high fat diet?; 2) What are the metabolic changes induced eNOS 
150 
  
overexpression?; and 3) Which plasma metabolites are sensitive to both 
high fat diet and eNOS? To address these questions we compared the 
metabolite profiles of each group of animals and identified the metabolic 
pathways most affected by diet and/or genotype.   
 
Experimental Procedures 
Animal studies: The C57BL/6J (wild-type; WT) mice were purchased from The 
Jackson Laboratory (Bar Harbor, ME).  The eNOS-TG mice, which express 
bovine eNOS under the control of the preproendothelin-1 promoter 338, were 
maintained on the C57BL/6J background.  At 8 weeks of age, male mice were 
placed on a 10% low fat diet (LFD; Research Diets, Inc., #D12450B), a 60% high 
fat diet (HFD; Research Diets Inc., #D12492) or a custom formulated 60% high 
fat diet containing GW4064 and maintained for 6 additional weeks. The custom 
GW4064 diet was produced by Research Diets Inc. and was formulated by 
adding GW4064 (Sigma, #G5172) to the HFD (#D12492) at a concentration of 
180 mg of compound/kg of diet. Water and diet were provided ad libitum. Body 
weights were recorded weekly.  During the 7th week of feeding, body composition 
analysis and glucose and insulin tolerance tests were performed. All other 
variables were evaluated after euthanasia.  All procedures were approved by the 




Glucose and insulin tolerance tests: As described previously 339, glucose 
tolerance tests were performed following a 6 h fast by injection (i.p.) of D-glucose 
(1 mg/g) in sterile saline. Insulin tolerance tests were performed on nonfasted 
animals by i.p. injection of 1.5 U/kg Humulin R (Eli Lilly, Indianapolis, IN). 
 
Body composition: Body composition was measured by dual-energy X-ray 
absorptiometry (Dexascan) using a mouse densitometer (PIXImus2; Lunar, 
Madison, WI).  
 
Metabolomic analysis of plasma: Whole blood was collected from WT and 
eNOS-TG mice fed a LFD or HFD for 6 weeks by cardiac ventricular puncture 
following a 16 hour fast. EDTA was added to whole blood samples to prevent 
coagulation and plasma was separated from red blood cells by centrifugation. 
Samples were shipped to Metabolon, Inc. (Durham, NC) for analysis. Metabolites 
were extracted with methanol and relative metabolite abundance was measured 
by GC/MS or LC/MS/MS exactly as described before 286. Metabolites with 
missing values were imputed by replacing missing values with half of the 
minimum positive value in the original data.  Metabolites with greater than 57% of 
the values missing were omitted from the analysis. After a generalized logarithm 
transformation, the data were autoscaled, i.e., mean-centered and divided by the 
standard deviation of each variable.  This step was performed to transform the 
intensity values so that the distribution was more Gaussian. Values between 
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groups were then compared using t-tests.  Univariate (e.g., volcano plots), 
multivariate (e.g., PLS-DA), cluster (heatmap and dendogram), and Z-score 
analyses were then performed. Z-scores were calculated using the equation: 
 
    
 
 ; where   is the raw score,   is the mean of the population and   is the 
standard deviation of the entire population.  Most analyses were performed using 
Metaboanalyst 2.0 software (http://www.metaboanalyst.ca/) 288; Z-score plots 
were constructed in GraphPad 5.0 software using data derived from volcano plot 
analysis.    
 
Statistical analyses: Data are presented as mean ± SEM. Multiple groups were 
compared using one-way or two-way ANOVA, followed by Bonferroni post-tests. 
Unpaired Student’s t test was used for direct comparisons. Statistical analyses 
were performed with the program “R” http://cran.r-project.org/, Metaboanalyst 
(http://www.metaboanalyst.ca/), and/or GraphPad 5.0.   A P value less than 0.05 
was considered significant. 
Plasma bile acid measurements: Total bile acids were measured using a liquid 
stable enzymatic colorimetric assay (Randox Laboratories, #BI3863) and 
analyzed by a Cobas Mira Plus 5600 Autoanalyzer (Roche, Indianapolis, IN). 
 
Results 
Overexpression of eNOS prevents diet induced obesity. To examine the role 
of eNOS in the regulation of systemic metabolism, mice overexpressing eNOS 
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(eNOS-TG) and C57BL/6J (WT) mice were placed on a low fat diet (LFD) or high 
fat diet (HFD) for six weeks. In agreement with our previous results, high fat-fed 
eNOS-TG mice were protected against diet-induced obesity and gained 50% less 
weight than high fat-fed WT mice (Fig. 32B). Dexascan analysis confirmed that 
the body fat percentage of the eNOS-TG mice was significantly lower and lean 
mass was significantly higher compared with WT mice after high fat feeding (Fig. 
32C,D). 
 
Plasma metabolomic analysis. To understand how overexpression of eNOS 
prevents diet-induced obesity in mice in greater detail, we measured the relative 
abundance of circulating metabolites in the plasma of WT and eNOS-TG mice on 
low or high fat diets. This analysis led to the identification of 298 metabolites. 
Using levels of these metabolites and excluding the genotype and diet group for 
each animal (i.e., WT LFD), we performed a multivariate (PLS-DA) analysis of 
the data. We found that group separation distance was significantly different 
when groups were separated based on their given characteristic (genotype and 
diet) rather than a randomly assigned variable. This indicates that the individuals 
within each group are more similar to each other than if they were placed in any 
other randomly assembled group.  
After PLS-DA confirmed that the experimental animal groups were distinct, 
we interrogated the differences in metabolite profiles between the groups. There 
were 34 metabolites that were significantly different between low fat- and high  
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Figure 32. Overexpression of eNOS prevents diet-induced obesity. Weight 
gain and adiposity measurements from WT and eNOS-TG mice fed a low fat 
(LFD) or high fat diet (HFD): (A) Body weights during 6 weeks of high or low fat 
feeding, n = 7 per group; (B) Summarized weight gain over the course of 6 
weeks of HF feeding, n = 7 per group; (C) Body fat percentage and (D) lean 
mass percentage following 6 weeks of diet measured by Dexascan analysis. n = 









fat-fed WT mice, 39 between low fat-fed WT and low fat-fed eNOS-TG mice, and 
41 between high fat-fed WT and high fat-fed eNOS-TG mice. However, each of 
these metabolites may not have been unique to only one comparison of animal 
groups. For instance, of the 34 metabolites that were significantly different 
between the low fat- and high fat-fed WT mice, 8 were also significantly different 
between the low fat-fed WT and low fat-fed eNOS-TG groups. Further, 10 of the 
34 metabolites that were significantly different between low fat- and high fat-fed 
WT mice were also significantly different between the high fat-fed WT and eNOS-
TG groups. Finally, 3 metabolites were significantly different in each comparison 
between the groups. This is illustrated by the Euler diagram in Figure 33 with 
each comparison between animal groups represented by a separate oval. The 
number of significantly different metabolites between these groups is in 
parentheses. In the regions where the ovals overlap, the number represents the 
number of metabolites that are shared between those comparisons of different 
animals. 
  
Plasma metabolic changes due to diet. As stated above, of the 298 
metabolites identified, 34 were significantly different between the low and high 
fat-fed WT mice. Volcano plot analysis showed that 12 of these metabolites were 
increased and 22 were decreased after high fat feeding (Fig. 34A). To delineate 
the biological relationships between metabolites that changed, we used the 
MetPA tool of Metaboanalyst 2.0 for pathway analysis. Pathways were calculated 
as the sum of the importance measures of the matched metabolites normalized 
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Figure 33. Changes in the plasma metabolome due to high fat feeding or 
eNOS overexpression.  Euler diagram showing the set-theoretic relationships 
between WT and eNOS-TG mice fed a low fat (LFD) or high fat diet (HFD). Total 
number of significantly different metabolites between the groups is shown in 
parentheses. Number of significantly different metabolites shared between 
groups is in the overlapping region of the corresponding groups. Diagram 








by the sum of the importance measures of all metabolites in each pathway 288. 
The highest pathway impact value was related to branched chain amino acid 
(BCAA) biosynthesis (i.e., valine, leucine and isoleucine) while 
glycerophospholipid metabolism and glyoxalate and dicarboxylate metabolism 
were also elevated. The pathway with the highest statistical significance was 
primary bile acid synthesis (Fig. 34B).   
 A Z-score analysis was then performed and metabolites that were 
significantly changed by more than 60% were plotted (Fig. 35). Metabolites that 
were lower in the high fat-fed group were mostly lipids (lysolipids and long chain 
fatty acids). Dicarboxylic fatty acids (decanedioate, tetradecanedioate, 
hexadecanedioate and octadecanedioate) also were lower in high fat-fed mice.  
Additionally, 1,5-anhydroglucitol (a marker of glycemic control) and members of 
the bile acid metabolism pathway (β-muricholate, cholate, taurocholate) were 
reduced. Sphingolipids (palmtioyl sphingomyelin and stearoyl sphingomyelin) 
and markers of cysteine metabolism (S-methylcysteine and cystine) were among 
the metabolites that were increased.    
 
Plasma metabolic changes due to genotype. To delineate the systemic 
metabolic changes that are induced by eNOS overexpression, similar analyses 
as described above were performed on the 39 metabolites that were significantly 
different between the low fat-fed WT and eNOS-TG mice. Volcano plot analysis 
identified that 13 metabolites were increased and 26 decreased in the eNOS-TG 
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Figure 34. Plasma metabolic changes due to diet. Metabolomic analyses of 
plasma from WT mice fed a low fat (LFD) or high fat diet (HFD) for 6 weeks: (A) 
Univariate analysis: Volcano plot of metabolites. Those metabolites that 
significantly increased are in the quadrant on the right side of the plot and those 
that significantly decreased are on the left (p<0.05, t-test); (D) Metabolites found 
to be significantly different were subjected to pathway impact analysis using 
Metaboanalyst MetPA and the Mus musculus pathway library. Fisher’s exact test 
was used for overrepresentation analysis, and relative betweenness centrality 








Figure 35. Z-score plot analysis of metabolite changes in plasma from low 
and high fat-fed mice. WT mice were fed a low fat (LFD) or high fat diet (HFD) 
for 6 weeks. Data are shown as standard deviations from the mean of LFD. Only 
metabolites that increased significantly and those that decreased by >60% are 
shown. Each point represents one metabolite in one sample. The color of 
metabolite indicates the superpathway to which it belongs: green - lipid 








compared with the WT mice (Fig. 36A). Metabolic pathway analysis (Fig. 36B) 
showed that -linolenic acid metabolism had a very high pathway impact value 
and was highly significant. Other significant pathways were BCAA metabolism, 
glycerophospholipid metabolism, pantothenate and CoA biosynthesis and lysine 
metabolism.  
In the eNOS overexpressing mice several markers of BCAA metabolism 
(isovalerylcarnitine, propionylcarnitine, isobutyrylcarnitine, and 4-methyl-2-
oxopentanoate) and bile acid metabolism (taurodeoxycholate, deoxycholate, and 
cholate) were significantly increased as shown in the Z-score plot (Fig. 37). 
Lysolipids and long chain fatty acids were decreased in the low fat-fed eNOS-TG 
compared with low fat-fed WT mice.  
Metabolic changes in high fat-fed WT and eNOS-TG mice were also 
considered. Between groups there were 41 metabolites that were significantly 
different; as determined by volcano plot analysis, 28 were increased in the 
eNOS-TG mice while 13 decreased (Fig. 38A). After metabolic pathway analysis 
was performed (Fig. 38B) three pathways were found to have both high pathway 
impact values and significance: -linolenic acid metabolism, BCAA biosynthesis, 
and ubiquinone and terpenoid biosynthesis. Other significant pathways were 
arginine and proline metabolism, bile acid biosynthesis, histidine metabolism and 
β-alanine metabolism.  
Similar to the metabolic changes in low fat-fed eNOS-TG mice, markers of 
bile acid metabolism (β-muricholate, cholate, deoxycholate, taurocholate, 
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Figure 36. Plasma metabolic changes due to genotype. Metabolomic 
analyses of plasma from WT and eNOS-TG mice fed a low fat diet (LFD) for 6 
weeks: (A) Univariate analysis: Volcano plot of metabolites. Those metabolites 
that significantly increased are in the quadrant on the right side of the plot and 
those that significantly decreased are on the left (p<0.05, t-test); (D) The 
metabolites found to be significantly different were subjected to pathway impact 
analysis using Metaboanalyst MetPA and the Mus musculus pathway library. 
Fisher’s exact test was used for overrepresentation analysis, and relative 
betweenness centrality was used for pathway topology analysis. n = 14 animals: 







Figure 37. Z-score plot analysis of metabolite changes in plasma from low 
fat-fed WT and eNOS-TG mice. WT and eNOS-TG mice were fed a low fat diet 
(LFD) for 6 weeks. Data are shown as standard deviations from the mean of WT 
LFD. Only metabolites that increased significantly and those that decreased by 
>60% are shown. Each point represents one metabolite in one sample. The color 
of metabolite indicates the superpathway to which it belongs: green - lipid 










Figure 38. Plasma metabolic changes due to genotype in obesity. 
Metabolomic analyses of plasma from WT and eNOS-TG mice fed a high fat diet 
(HFD) for 6 weeks: (A) Univariate analysis: Volcano plot of metabolites. 
Metabolites that significantly increased are in the quadrant on the right side of the 
plot and those that significantly decreased are on the left (p<0.05, t-test); (D) 
Metabolites found to be significantly different were subjected to pathway impact 
analysis using Metaboanalyst MetPA and the Mus musculus pathway library. 
Fisher’s exact test was used for overrepresentation analysis, and relative 
betweenness centrality was used for pathway topology analysis. n = 14 animals: 







taurodeoxycholate and taurochenodeoxycholate) and BCAA metabolism 
(isovalerylcarnitine, isobutyrylcarnitine, propionylcarnitine, N-acetylleucine, 
leucine and valine) were significantly elevated in eNOS-TG compared with WT 
mice on a high fat diet (Fig. 39). Phenylalanine and tyrosine metabolism and urea 
cycle intermediates were also significantly elevated. Levels of long chain fatty 
acids, lysolipids, and essential fatty acids were major metabolites that were lower 
in the high fat-fed eNOS-TG compared with WT mice.     
 
Plasma metabolic changes due to diet and genotype. To visualize the 
metabolic changes more likely to be involved in eNOS-induced resistance to diet-
induced obesity, we identified those metabolic changes occurring in HF-fed WT 
mice that were reversed by eNOS overexpression. For this we plotted the Z-
scores of plasma metabolites found to be significantly different between WT LFD 
and WT HFD mice (as in Fig. 35) and then superimposed the Z-scores from 
eNOS-TG mice (Fig. 40). Although most metabolites were affected similarly by 
HFD in both gentoypes, 3-dehydrocarnitine, 3-indoxyl sulfate, cholate, 
taurocholate, and leucine were significantly decreased by HFD in WT mice but 
were comparatively higher in high fat-fed eNOS-TG mice. This could indicate that 
the metabolic pathways to which they belong may be important in the mechanism 




Figure 39. Z-score plot analysis of metabolite changes in plasma from high 
fat-fed WT and eNOS-TG mice. WT and eNOS-TG mice were fed a high fat diet 
(HFD) for 6 weeks. Data are shown as standard deviations from the mean of WT 
HFD. Only metabolites that increased significantly and those that decreased by 
>60% are shown. Each point represents one metabolite in one sample. The color 
of metabolite indicates the superpathway to which it belongs: green - lipid 








Figure 40. Modified Z-score plot analysis of metabolite changes in plasma 
from low fat-fed WT and both high fat-fed WT and eNOS-TG mice. WT mice 
were fed a low fat (LFD) or high fat diet (HFD) and eNOS-TG mice were fed a 
HFD for 6 weeks. Data are shown as standard deviations from the mean of WT 
LFD. Metabolites that increased significantly and those that decreased by >60% 
between the WT LFD and HFD (black circles) are shown. Levels of those 
metabolites were then compared between WT LFD and eNOS-TG HFD and 








Changes in bile acids and fatty acids are induced by diet and eNOS 
overexpression. Analyses described above suggested that bile acid 
metabolism, which can regulate energy expenditure and obesity 421, 422, and 
carnitine metabolism, which is involved in regulating fatty acid oxidation, might be 
significant pathways contributing to eNOS-induced resistance to obesity.  
Therefore, to obtain additional insights into these metabolic changes, we plotted 
changes in bile acids and fatty acid metabolism.  In WT mice, HFD significantly 
decreased 5 of the 7 bile acids compared with WT, low fat-fed mice (dotted line, 
Fig. 41A). In the context of LFD, eNOS overexpression was associated with 
higher levels of three of the bile acids compared with WT (Fig. 41A). On HFD, 
eNOS-TG mice had significantly higher levels of all but one bile acid compared 
with high fat-fed WT mice (Fig. 41A). When compared with WT LFD mice, levels 
of bile acids were not significantly different in eNOS-TG mice fed a HFD, with the 
marked exception of deoxycholate and taurodeoxycholate which were 
significantly elevated.   
Bile acid signaling has been linked to increased fatty acid oxidation by increased 
PPAR 423 and PDK-4 424 expression in liver. Our previous metabolic pathway 
analyses showed that -linolenic acid metabolism had the highest pathway 
impact and statistical significance of any pathway in eNOS-TG mice when 
compared to WT on both diets (Fig 36B and 38B). Together these results led us 
to investigate if levels of markers of fatty acid metabolism mirrored those of bile 
acids. Indeed, medium-chain, long-chain, and essential fatty acids were 
decreased in eNOS-TG mice when compared with WT on both LFD (data not 
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Figure 41. Changes in bile acid and fatty acid levels induced by diet and 
eNOS overexpression. Plasma levels of (A) bile acids obtained from 
metabolomics analyses from WT mice fed a high fat diet (HFD) (white hatched 
bars) or eNOS-TG mice fed a low fat diet (LFD) (blue bars) or HFD (blue hatched 
bars) for 6 weeks. n = 7 per group; *p<0.05, **p<0.01 and ***p<0.001 vs. WT of 
same diet; #p<0.001 vs. WT LFD. (B) Plasma levels of fatty acids from HFD-fed 
WT (white bars) and eNOS-TG (blue bars) mice. Data are expressed as fold 
change vs. WT HFD. n = 7 per group, *p<0.05 vs. WT HFD. 
 








shown) and HFD (Fig. 41B). A majority of fatty acid species that were not 
significantly decreased were either saturated fats with an odd numbered chain 
length or polyunsaturated fats. These data suggest that eNOS overexpression 
increases bile acid synthesis, which could increase the oxidation of fatty acids 
and augment overall energy expenditure  
 
Preventing bile acid synthesis does not prevent diet-induced obesity. To 
test whether the lean phenotype of eNOS-TG mice is due to eNOS-induced 
changes in bile acid metabolism, eNOS-TG mice were placed on a HFD for 6 
weeks along with a synthetic inhibitor of bile acid synthesis, GW4064, which is a 
farensoid X receptor (FXR) agonist that decreases bile acid biosynthesis and bile 
acid pool size in C57BL/6J mice 421. We reasoned that if bile acids are 
responsible for the lean phenotype of eNOS-TG mice, decreasing their synthesis 
should increase weight gain. Treatment of eNOS-TG mice with the bile acid 
inhibitor showed a trend toward decreased levels of circulating bile acids (Fig. 
42B), however there was no difference in weight gain compared with those fed 
HFD alone (Fig. 42A). Likewise, glucose tolerance, insulin sensitivity and fasting 
blood glucose levels were unaffected by the GW4064 supplementation (Fig. 42C-
i-iii). These findings indicate that eNOS overexpression increases systemic 




Figure 42. Preventing bile acid synthesis does not prevent diet-induced 
obesity. eNOS-TG mice were fed a high fat diet (HFD) with or without GW4064 
for 6 weeks. Body weight gain, glucose tolerance and insulin sensitivity were 
examined: (A) Body weight gain by week of HFD. n = 5-6 per group; (B) Levels 
of plasma bile acids. n = 4-6 per group; (C) Glucose tolerance test (GTT) area 
under the curve (AUC), insulin tolerance test (ITT) AUC and fasting blood 









The major goal of this study was to identify systemic metabolic changes 
that could underlie the lean phenotype induced by eNOS overexpression. During 
this analysis we considered that eNOS overexpression could either prevent a 
defect caused by high fat feeding or increase metabolic pathways that would 
otherwise promote resistance to obesity. Using metabolomics analysis, we 
identified several metabolic pathways that were significantly affected by high fat 
feeding or overexpression of eNOS. We found that, bile acid metabolites were 
significantly decreased by high fat feeding and significantly elevated due to 
eNOS overexpression. Additionally, after high fat feeding, bile acids remained 
significantly elevated in eNOS-TG compared to WT mice. This indicated that 
eNOS protects from a diet-induced suppression of bile acid metabolism and may 
play a role in the resistance to obesity observed in eNOS-TG mice. We also 
found evidence of significantly increased fatty acid metabolism in eNOS-TG 
mice. Therefore, we hypothesized that eNOS overexpression stimulates bile acid 
synthesis, which in turn increases both fatty acid oxidation and energy 
expenditure, providing intrinsic resistance to diet-induced obesity. If this were 
true, we reasoned that inhibiting bile acid synthesis would cause an accentuated 
weight gain in eNOS-TG mice on a HFD. Alternatively, bile acid-independent, 
eNOS-dependent changes in fatty acid metabolism could be important for the 
maintenance of a lean phenotype.  
To understand how eNOS overexpression induces a lean phenotype 
during nutrient excess, we first investigated the systemic metabolic changes that 
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occur in WT mice on a HFD. Metabolomic analyses showed several metabolic 
pathways affected in obesity. Primarily, HFD altered fatty acid and lipid 
metabolism (mainly lysophospholipid and sphingolipids), bile acid metabolism, 
glucose and cholesterol metabolism and markers of oxidative stress.  
Lysophospholipid metabolism and its role in the regulation of obesity and 
systemic metabolism are unclear. The term 'lysophospholipid' (LPL) refers to any 
phospholipid that is missing one of its two O-acyl chains. Thus, LPLs have a free 
alcohol at either the sn-1 or sn-2 position. The prefix 'lyso-' derives from the early 
observations that LPLs were hemolytic, however, it is now used to refer generally 
to phospholipids missing an acyl chain. Lysophosphatidylcholine (lysoPC) is 
found in small amounts in most tissues and is formed by hydrolysis of 
phosphatidylcholine by the enzyme phospholipase A2, as part of the de-
acylation/re-acylation cycle that controls its overall molecular composition 425. In 
plasma, significant amounts of lysoPC are formed by a specific enzyme system, 
lecithin:cholesterol acyltransferase (LCAT), which is secreted from the liver 426. 
The enzyme catalyzes the transfer of the fatty acids of position sn-2 of 
phosphatidylcholine to the free cholesterol in plasma, with formation of 
cholesterol esters and lysoPC 427. LPLs play a key role in lipid signaling by 
binding to the LPL receptors (LPL-R) 428. LPL-Rs are members of the G protein-
coupled receptor family of integral membrane proteins 429.  LysoPCs are known to 
account for 5–20% of all phospholipids in the serum 430 and have been 
suggested to be closely associated with endothelial dysfunction, oxidative stress, 
inflammation, atherogenesis, and obesity 430. 
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Since lysoPCs have a relatively short half-life, they are thought to be 
metabolic intermediates that are produced during the formation or breakdown of 
other lipids. LysoPCs can have different combinations of fatty acids of varying 
lengths and saturation attached at the C-1 (sn-1) position. Fatty acids containing 
16, 18 and 20 carbons are the most common. In our analysis, several species of 
lysoPC, including lysoPC 16:1 and 18:1 were decreased while one, lysoPC 17:0, 
was increased by HFD. These findings are in accordance with a previous study 
that showed decreased levels of lysoPC 16:1 and 18:1, as well as lysoPC 14:0, 
15:0, 16:0, 17:1, 18:2, 19:0, 20:1 and 20:4 while lysoPC 17:0, 18:0 and 18:3 were 
increased in diet-induced obese mice 431. Additional studies have shown 
decreased serum levels of lysoPC 18:1 and increased lysoPCs 14:0 and 18:0 in 
obese men 432 as well as increased lysoPC 18:0 in high fat-fed pigs 433. While 
there was an association between specific lysoPC species and obesity, further 
study is needed to elucidate their role in regulation of body composition.   
Decreased levels of lysoPCs measured in obesity could indicate a 
decrease in the activity of the enzymes responsible for their esterification. 
However, studies in mice lacking LCAT, the main generator of circulating 
lysoPCs, demonstrate a resistance to diet-induced obesity and insulin 
insensitivity 434. Further, LDLR/LCAT double knockout mice, in addition to 
remaining lean after high fat feeding, display ectopic depositions of brown 
adipocytes in skeletal muscle 434. Though phospholipids, generally, were 
decreased in these mice, the authors did not specify as to their species. 
Conversely, overexpression of LCAT in mice has been shown to increase plasma 
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HDL and markedly reduced VLDL, LDL and triglyceride levels, but offered no 
protection from the development of diet-induced atherosclerosis 435. While our 
analysis is suggestive of a decreased synthesis of circulating lysoPCs by LCAT, 
further examination of the activity and expression of the enzyme would be 
necessary to determine the mechanism underlying these changes.  
As in our previous analysis of adipose tissue, we found that the plasma 
levels of sphingolipid metabolites were profoundly increased in obesity. Palmitoyl 
sphingomyelin and stearoyl sphingomyelin were the most significantly increased 
metabolites high and low fat-fed animals. As mentioned previously (Chapter II), 
the breakdown of sphingomyelin could yield significant amounts of ceraminde, 
which is a potent inhibitor of insulin signaling. Plasma ceramide levels are 
elevated in obese individuals and correlate with the severity of insulin resistance 
436.  
Carbohydrate metabolism and glucose handling were also altered by 
HFD, specifically, glucose and mannose levels were elevated while 1,5-
anhydroglucitol (1,5-AG), an important marker of glycemic control 437, was 
significantly decreased. This evidence of disrupted glucose metabolism is 
consistent with our previous data that six weeks of high fat feeding is sufficient to 
induce glucose and insulin intolerance (Chapter II, Fig. 4).  
Bile acids have been shown to be potent regulators of metabolism. 
Synthesized from cholesterol in the liver, bile acids are secreted into the 
intestines to aid in digestion, primarily fat emulsion 438. Recently, new roles for 
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bile acids as important signaling molecules have also been described. Bile acid 
signaling has been shown to augment energy expenditure 439, lipid and glucose 
homeostasis 440, 441, and body composition 421. Through its control of short 
heterodimer partner (SHP) expression, FXR has been shown to downregulate 
hepatic fatty acid and triglyceride synthesis 440 while bile acid supplementation 
increased brown adipose tissue energy expenditure and prevented obesity and 
insulin resistance in mice 439. Conversely, decreasing bile acid pool size 
worsened obesity and diabetes in high fat-fed mice 421. Further, there is evidence 
supporting an NO-induced increase of bile acid synthesis. Perfusion of livers with 
NO donors increased bile acid outflow 442, 443 while inhibition of NOS reduced the 
biosynthesis of bile acids by inhibiting the activity of hepatic Cyp7A1 444, the rate-
limiting enzyme in bile acid production 445.  Bile acids can also increase 
mitochondrial biogenesis. Through the binding and activation of the G-coupled 
receptor, TGR-5, in brown adipose tissue and skeletal muscle, bile acids trigger a 
signaling cascade that activates PGC-1, a master regulator of mitochondrial 
biogenesis 439.  These data support the idea that increased bile acid synthesis in 
eNOS-TG mice could have a significant impact on body composition and energy 
expenditure.  
The relationship of bile acids and triglyceride metabolism has been 
established for decades 445. In clinical trials, dyslipidemic patients given bile acid-
sequestering resins exhibited increased plasma triglyceride and VLDL levels 446, 
447. Additionally, patients with deficiencies in CYP7A1 are also characterized by 
increased plasma triglyceride concentrations 448. In rodent models, FXR 
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activation has been linked to lower plasma triglycerides 440, 449 by the induction of 
hepatic PPAR expression 423. In our analysis, overexpression of eNOS induced 
a broad decrease in plasma FFA levels, predominantly long chain fatty acids and 
essential fatty acids. Further, on HFD levels of the β-oxidation intermediates, 3-
hydroxyoctanoate and 3-hydroxydecanoate, were decreased while the carnitine-
conjugated end product, propionylcarnitine, was higher in eNOS-TG mice 
compared with WT mice. Taken together, these data suggest that eNOS 
overexpression increased β-oxidation and decreased fatty acid synthesis.  
Studies in NO donor-treated rat hepatocytes showed similar results by 
increasing β-oxidation in a cGMP-dependent manner and decreasing lipid 
synthesis 450. Additionally, inhibitors of NOS 451 and deletion of eNOS increased 
hepatic lipid synthesis 452. The eNOS KO mice also showed decreased 
expression of genes involved in β-oxidation and increased expression of 
neolipogenic genes in skeletal muscle 337. Collectively, these data suggest that 
eNOS regulates lipid metabolism, possibly via a PPAR-mediated mechanism 
453. As shown previously, PPAR was elevated in the adipose tissue of eNOS-
TG mice (Chapter III) which supports the hypothesis that eNOS overexpression 
increases fatty oxidation capacity.  
Because the liver is the site of both bile acid synthesis and fatty acid 
metabolism, we hypothesized that eNOS overexpression increases bile acid 
synthesis, and, in doing so, might increase fat utilization, either directly by 
increasing PPARα activity in the liver, or indirectly, by promoting increased 
thermogenesis in other peripheral tissues, such as brown adipose tissue. 
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Activation of FXR by the synthetic agonist GW4064 was shown previously to be 
sufficient to decrease bile acid levels and energy expenditure, thereby 
accentuating diet-induced weight gain and insulin resistance 421. However, in our 
study, bile acid inhibition had no effect on weight gain, glucose handling or insulin 
sensitivity in eNOS-TG mice.   
These data appear to indicate that eNOS overexpression increases fatty 
acid metabolism and systemic energy expenditure by a bile acid-independent 
mechanism. The increase in PPAR expression measured in the adipose tissue 
of eNOS-TG mice may indicate that eNOS overexpression has a direct effect on 
PPAR-mediated increased fatty acid oxidation in other tissues as well. To 
address this hypothesis, we plan to measure PPARα-driven genes in liver and 
skeletal muscle. Should results suggest a role for PPARα, future experiments 
would focus on pharmacological or genetic disruption of PPAR in the eNOS 
overexpressing mice. For example, crossing PPAR knockout mice with eNOS-
TG mice and feeding a high fat diet could be an especially revealing experiment. 
If these mice were to become obese as a result of high fat feeding we would 
have strong evidence to support the claim that eNOS protects from obesity via a 
PPAR-mediated mechanism. Additionally, activation of PPAR in WT mice 
during high fat feeding could also be informative. Fibrates are a class of PPAR 
agonists that have been used in combination with statins to lower plasma 
cholesterol and triglycerides 454 and have been shown to reduce micro- and 
macrovascular risk 455. Fibrate treatment during high fat feeding of WT mice 
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would provide additional insights into the role of PPAR-induced fatty acid 
metabolism on the development of metabolic disease.   
Fibrates have also been shown to promote the catabolism of BCAAs 456. 
In our analysis, plasma levels of BCAAs and short-chain acyl carnitines were 
decreased in high fat-fed WT mice and increased in the eNOS-TG mice, similar 
to our previous findings in adipose tissue (Chapter III). It has been shown before 
that plasma BCAAs are increased in obese and diabetic humans and rodents 66, 
312, but the significance of BCAAs in regulating adiposity or insulin resistance is 
unclear. BCAAs have also been shown to promote insulin resistance 312. Despite 
lower levels of weight gain, rats fed a BCAA/HF diet remain insulin resistant. 
Sustained insulin resistance in these rats has been linked to mTOR activation 312, 
which induces insulin resistance by phosphorylating IRS1 457, 458. 
BCAA supplementation has been shown to have favorable effects on diet-
induced metabolic disease. Feeding leucine prevented obesity in rodents 459, 460, 
and was associated with lower adiposity in humans 461, while isoleucine 
decreased tissue TG accumulation and adiposity and increased expression of 
PPAR and UCPs in diet-induce obese mice 462. Additionally, increasing BCAA 
levels by deletion of BCATm, the enzyme that catalyzes the first step in BCAA 
metabolism, completely prevents HFD-induced insulin resistance and adiposity in 
mice 311. Furthermore, BCAAs as well as 3C-acylcarnitines increase 
mitochondrial biogenesis and promote energy expenditure 311, 354-356. Therefore, it 
is possible that BCAA levels in high fat-fed eNOS-TG mice is due to increased 
protein degradation and synthesis, which dissipates excess energy.  
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Limitations of this study are inherent to the descriptive approach employed 
by metabolomics analyses. Metabolomics is a powerful analytical tool to 
interrogate wide-ranging changes in different experimental samples. However, 
metabolomics analysis is designed mainly to generate new hypotheses as 
opposed to test specific hypotheses. These analyses can be very useful in 
nutritional research and biomarker discovery, but they give only a “snapshot” of 
changes that are occurring at that moment.  Furthermore, current libraries of 
known metabolites and metabolic pathway models are incomplete. Nevertheless, 
such approaches are indispensable for identifying novel pathways that might be 
important to health and disease. 
In summary, this study identified significantly altered metabolic pathways 
due to high fat feeding and eNOS overexpression. Bile acid metabolism and fatty 
acid metabolism pathways were significantly decreased by nutrient excess in WT 
mice but were rescued by eNOS overexpression. Inhibiting bile acid synthesis 
did not produce an obese phenotype in eNOS-TG mice on HFD; however, eNOS 
shows a clear influence on fatty acid metabolism. Future studies will focus on the 
mechanism(s) by which increased eNOS activity regulates fatty acid metabolism 






We undertook the studies presented here were to develop a better 
understanding of how NO regulates metabolism. For this, we examined 
metabolic changes that accompany diet-induced obesity and insulin resistance 
and we assessed the impact of increasing NO during nutrient excess. Our 
hypothesis was that increased NO derived from eNOS prevents diet-
induced obesity by promoting adipose tissue browning and increasing 
systemic metabolism. To address this hypothesis, we examined whether 
overexpression of eNOS was sufficient to promote metabolic alterations in WAT 
during high fat feeding that would prevent obesity and insulin resistance. To 
obtain a more comprehensive view, we investigated changes in systemic 
metabolism that were induced by eNOS.  
 As discussed in Chapter II, we first examined the metabolic and 
bioenergetic changes occurring in WAT with obesity. After six weeks of high fat 
feeding, metabolomic analyses showed marked changes in glycerolipid and 
amino acid metabolism, with most metabolites showing a decrease in WAT of 
obese mice.  Levels of succinate, however, increased significantly in WAT from 
high fat-fed mice, suggesting changes in mitochondrial metabolism. Furthermore, 
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we found changes indicative of mitochondrial remodeling, decreased 
mitochondrial bioenergetic capacity and striking decreases in eNOS abundance. 
Collectively, these results revealed a range of coordinated changes in 
mitochondrial function that might be contributing to the “whitening” of adipose 
tissue in obesity.   
 To examine the significance of in eNOS downregulation in WAT, we 
investigated whether increasing eNOS expression would prevent obesity and its 
metabolic consequences. In Chapter III, we present data showing that 
endothelial-specific overexpression of eNOS prevents diet-induced obesity and 
reduces plasma levels of insulin, TGs and FFAs, without affecting systemic 
glucose intolerance. The eNOS-TG mice displayed a higher metabolic rate and 
reduced adipocyte hypertrophy in WAT. Metabolomic analyses indicated an 
increase in fatty acid oxidation in WAT that was reflected by an increase in the 
expression levels of PPAR- and PPAR- genes, higher abundance of 
mitochondrial proteins and increased rate of mitochondrial oxygen consumption. 
These findings demonstrate that eNOS has anti-obesogenic effects that prevent 
high fat diet-induced obesity without affecting systemic insulin resistance, in part 
by stimulating metabolic activity in WAT.  
 Although effects of eNOS overexpression on WAT were quite profound, 
we questioned whether these effects could account fully for the increase in 
whole-body energy expenditure and the lean phenotype observed in eNOS-TG 
mice. Therefore, as discussed in Chapter IV, we studied effects of eNOS 
overexpression on systemic metabolism. Measurements of plasma metabolites in 
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eNOS-TG mice were consistent with increases in fatty acid, bile acid and BCAA 
metabolism. However, our experiments to decrease bile acids in eNOS-TG mice 
did not markedly affect on body composition and glucose or insulin handling 
suggesting that the metabolic effects of eNOS overexpression on fatty acid 
metabolism are not mediated by bile acids. From these findings we propose that 
eNOS increases BCAA metabolism thereby increasing PPAR activity in the liver 
and possibly skeletal muscle leading to increased fat utilization. Further 
elucidation of the regulatory effects of eNOS on BCAA metabolism and its effects 
on fatty acid metabolism could help understand the mechanism by which eNOS 
increases systemic energy expenditure and prevents adiposity.  
 Nevertheless, data obtained from studies so far support a pivotal role of 
NO as a central regulator of energy metabolism and body composition. This 
regulation, however, is inherently complex and growing evidence demonstrates 
divergent effects of NO depending on its source and anatomic location. In the 
sections that follow, our findings are discussed in the context of the known 
interactions between NO, its sources of generation and obesity and insulin 
resistance.  
 
Regulation of obesity and insulin resistance by NO 
In one approach, pharmacological studies as well as gain-of-function and 
loss-of-function studies helped in elucidating the critical roles for NO in regulating 
obesity and insulin resistance. Previously, supplementation with the NOS 
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substrate, L-arginine, and inhibition of NOSs were the most common 
pharmacological approaches used to determine how NO regulates body 
composition and insulin sensitivity.  Genetic approaches, utilizing mice in which 
components integral to the synthesis of NO have been deleted or overexpressed, 
have led to further development of a model by which NO regulates systemic 
metabolism.  The model thus built is extensive in its complexity and integration 
and involves nearly all aspects thought to be important in regulating metabolic 
homeostasis. 
 
Lessons from pharmacological interventions 
Using primarily L-arginine and NOS inhibitors, early pharmacological 
studies showed that NO is a potent regulator of both energy intake and 
expenditure.  Interestingly, both L-arginine and NOS inhibitors prevent obesity 
and insulin resistance, albeit by different mechanisms.   
 
nNOS-derived NO increases food intake  
In rodents, L-arginine was shown to increase, and NOS inhibitors to 
decrease, food intake 193, 463-466.  These effects were due to NO activity in the 
brain, impinging on the leptin and serotonergic systems that regulate hunger. 
Leptin, given intracranially, was found to diminish diencephalic NOS activity and 
decrease food intake and body weight gain, and intracranial co-administration of 
L-arginine antagonized this effect 467. Furthermore, intracerebroventricular 
injection of L-arginine, likely through stimulation of NOS activity, inhibited 
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serotonin-induced anorexia caused by IL-1β 468. Studies with NOS inhibitors have 
further solidified our understanding of the central effects of NO on hunger.  
Systemic administration of the NOS inhibitor, NG-nitro-L-arginine, reduced food 
intake in obese rats and increased serotonin metabolism in the cortex, 
diencephalon, and medulla pons, thereby implicating the central serotoninergic 
system in mediating the anorexic effect of NOS inhibitors 469. Other NOS 
inhibitors, such as L-NAME, promote weight loss and diminish food intake in 
ob/ob and db/db mice 465 and obese rats 470 and reduce adiposity and improve 
insulin sensitivity in high fat-fed mouse models 471.  Interestingly, 
intracerebroventricular administration of NG-monomethyl-L-arginine (L-NMMA) 
was shown also to regulate insulin secretion and peripheral insulin sensitivity 472, 
suggesting that centrally derived NO has effects that extend to distal nodes of 
systemic metabolism.  It is also possible that this effect contributes to the 
hyperphagic effects of NO, as insulin is well known to regulate hunger and satiety 
473-477. Taken together with numerous other studies demonstrating a role for NO 
in the regulation of hunger 478-482, it would appear that NO produced in the brain 
antagonizes anorectic signals and stimulates food intake. 
 
Evidence supporting a role of NO in energy expenditure and glucose and lipid 
metabolism 
Ostensibly, the reported anti-anorexic effects of NO might imply that by 
promoting food intake, increased levels of NO, e.g., that elicited by 
supplementation with L-arginine, should increase adiposity and insulin 
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resistance.  However, human studies have shown repeatedly that L-arginine 
supplementation has favorable effects on body composition and insulin sensitivity 
483-489.  Results from animal studies are in agreement: in rodents, L-arginine 
treatment has multimodal effects characterized by decreased fat mass, increased 
muscle mass, and improved insulin sensitivity. Despite promoting hyperphagia, 
L-arginine feeding reduced WAT mass, improved insulin sensitivity, and 
increased energy expenditure in mice 490. In rats, not only has dietary L-arginine 
supplementation been shown to reduce fat mass, but it appears to increase 
skeletal muscle and brown fat mass and reduce serum concentrations of 
glucose, TGs, FFAs, homocysteine, dimethylarginines, and leptin as well 491, 492. 
Similar salubrious systemic effects of L-arginine have been demonstrated in pigs 
493. Overall, these collective data suggest that L-arginine, and by inference, NO, 
has the capacity to reduce fat mass by increasing mitochondrial biogenesis, 
regulating brown adipose tissue signaling, and increasing the expression of 
genes that promote oxidation of energy substrates 494. 
Chronic treatment with sildenafil, which prevents the degradation of cGMP 
and is commonly prescribed to improve penile erectile function, improved insulin 
action and diminished obesity in high fat-fed mice 495. Shorter durations of 
sildenafil treatment have been shown to promote “browning” of white adipose 
tissue 496. While there are no reports that type 5-phosphodiesterase inhibitors 
such as sildenafil regulate obesity in humans, they have been shown to increase 
mitochondrial biogenesis in human adipose tissue ex vivo 497, suggesting at least 
the potential to increase energy expenditure.   
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Other drugs that affect NO production or function lend additional support 
to a role for NO in regulating insulin sensitivity. Beraprost (a stable prostaglandin 
analog) restores eNOS phosphorylation in endothelial-specific IRS-2 knockout 
mice and has been found to rescue capillary recruitment and to promote 
adequate insulin and glucose delivery to the skeletal muscle 217.  Insulin, L-
arginine, and sodium nitroprusside, by promoting S-nitro(sy)lation of key proteins, 
have been found to be particularly critical for regulating vascular endothelial 
insulin uptake and its transendothelial transport 498. Hence, NO derived from 
eNOS appears play an important role in regulating systemic glucose metabolism 
and insulin delivery to peripheral tissues. 
A characteristic feature of NO signaling is that effects of NO depend on its 
site of generation, concentration, and duration of application. Particularly 
interesting are the modes of action of NO in the liver, skeletal muscle, and 
pancreas.  Although chronic treatment with NOS inhibitors promote weight loss 
and insulin sensitivity in animal models 465, 470, 471, acute application of these 
inhibitors causes systemic insulin resistance 499. This is mediated in part by 
actions in the liver, which can regulate systemic responses to insulin 500.  
Administration of BH4, which is known to be oxidized to BH2 in the diabetic state 
501-503 and plays an important role in regulating coupled eNOS activity (see 
above), to STZ-induced diabetic mice lowered fasting blood glucose levels in an 
eNOS-dependent manner and improved glucose tolerance and insulin sensitivity 
in ob/ob mice 504.  This metabolic improvement was at least partially due to 
eNOS-mediated activation of AMPK in the liver, which suppressed hepatic 
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gluconeogenesis 504.  Hence, eNOS uncoupling in liver may be important for 
regulating systemic glucose metabolism.   
Several studies demonstrate an important role of eNOS and nitrogen oxides 
in the liver. For example, intraportal administration of NOS inhibitors was shown 
to cause insulin resistance, which was rescued by intraportal delivery of the NO 
and superoxide donor, SIN-1 505, 506.  Interestingly, when liver glutathione was 
first depleted by buthionine sulfoximine, the effects could not be rescued by 
sodium nitroprusside or SIN-1 506.  These results suggest that the formation of 
nitrosated glutathione (GSNO) in the liver might be important in mediating 
systemic responses to insulin. That intraportal delivery of glutathione methyl 
ester and SIN-1 enhances insulin sensitivity in rats would appear to support this 
view 507. 
 
The NO-HISS connection? 
How does NO (and its oxidation products) in the liver mediate systemic 
responses to insulin?  It has been suggested that the hepatic role of NO may 
relate to a hormone called ‘hepatic insulin-sensitizing substance (HISS)’.  This 
substance, for which there are only suggestive candidates (e.g., bone 
morphogenetic protein-9 508), appears to account for 55% of the glucose disposal 
by insulin. Briefly, it is posited that post-prandial elevations in insulin results in 
release of a hormone, i.e., HISS, from the liver that acts on skeletal muscle to 
promote glucose uptake 509, 510. Intriguingly, one study suggests that HISS, not 
insulin action, regulates the peripheral vasodilation generally attributed to insulin 
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511.  Atropine or hepatic surgical denervation inhibited the peripheral vascular 
actions of insulin, allegedly by blocking HISS release, whereas intraportal 
delivery of acetylcholine, which increases NOS activity, restored HISS release 
and insulin-mediated vasodilation 511. These findings are consistent with original 
studies showing that insulin-mediated vasodilation is dependent on NO 512, 513 
and that insulin-mediated skeletal muscle vasodilation contributes to insulin 
sensitivity in humans 514. Combined with other studies suggesting a role for NO in 
promoting the release of HISS 515-517, this suggests that the putative hormone 
could be an NO-regulated, liver-produced, endocrine mediator of classical EDRF 
crucial for glucose disposal.  However, (in addition to the identity of HISS) it 
remains unclear how this distally engendered mode of vasoregulation integrates 
physiologically (and pathologically) with the local effects of insulin and NO in the 
vasculature 214-217.   
 
Pancreatic effects of NO  
Extremely important for maintaining metabolic homeostasis, the pancreas 
utilizes NO to regulate their function. The pancreas is comprised of two types of 
glands: (1) exocrine glands, which secrete the bicarbonate and digestive 
enzymes needed to neutralize the acidic gastric contents entering the small 
intestine and to complete digestion of food, respectively; and (2) endocrine 
glands, i.e., the islets of Langerhans, which contain several types of secretory 
cells, including α cells, β cells, δ cells, and F cells.  Each of these cell types 
secretes multiple proteins, such as insulin (β cells), glucagon (α cells), and 
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somatostatin (δ cells). NO has been shown to affect both exocrine and endocrine 
functions of the pancreas 518, 519.   
With respect to insulin release, it appears that NO stimulates early, glucose-
induced insulin release, while it is responsible for cytokine (e.g., IL-1β)-mediated 
inhibition of insulin secretion.  This dual role of NO in regulating insulin secretion 
has been a subject of controversy (e.g., 520), which may be, in part, due to the 
mechanistic complexity regulating pancreatic insulin secretion; compounded by 
the multiple actions of NO.  The inhibitory actions of NO on insulin release 
appear to be due to iNOS-derived NO, which is implicated in the destruction of 
islet cells in type 1 diabetes 521, 522.  However, mechanisms regulating the insulin-
stimulating effects of NO 523-526 have been more difficult to elucidate. NO has 
been suggested to stimulate islet cell insulin secretion by inducing calcium 
release from mitochondria 527, which may be due to NO-mediated inhibition of 
respiration and mitochondrial depolarization. Nevertheless, the stimulatory 
effects of NO on insulin secretion are relatively subtle 526, which might explain 
why some studies suggest that NO is not involved in the initiation of insulin 
secretion from pancreatic islets 528, 529. 
 
Lessons from human studies and genetic interventions  
Considerable data suggests an association between genetic polymorphisms 
in NOS isoforms and insulin resistance. Notably, several studies have associated 
a T(-786)C variant of the eNOS gene with insulin resistance 530-532. Several other 
genetic variants in the eNOS locus are associated with T2D 533, susceptibility for 
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insulin resistance, hypertriglyceridemia, and low HDL 534, or worsened 
endothelial function in individuals prone to T2D 535.  Polymorphisms in the iNOS 
gene have been associated with higher plasma glucose and elevated waist/hip 
ratios 536, and variants in the iNOS gene promoter are associated with T2D 537. 
Genetic deletion, manipulation, and overexpression of NOS isoforms in mice 
have allowed for interrogation of mechanisms by which NO regulates metabolic 
health and disease.  In mice, it has been reported that deletion of eNOS causes 
insulin resistance, hyperlipidemia, and hypertension 336. While full gene deletion 
mimics human “metabolic syndrome,” even partial gene deletion of eNOS results 
in exaggerated insulin resistance, glucose intolerance, and hypertension induced 
by a high fat diet 538, 539. Mice lacking all NOS isoforms, i.e., eNOS/nNOS/iNOS 
triple knockout mice, demonstrate increased visceral obesity, hypertension, 
hypertriglyceridemia, and impaired glucose tolerance, and, it is interesting to 
note, that this is one of the few mouse strains to date to have spontaneous 
myocardial infarctions, apparently due to unstable coronary arteriosclerotic 
lesions 540. That NOS is important to insulin sensitivity was further shown by 
studies in mice in which overexpression of dimethylarginine 
dimethylaminohydrolase—an enzyme that catalyzes the breakdown of the 
endogenous inhibitor of NOS, ADMA—increased insulin sensitivity 541.  
 
Anti-obesogenic effects of eNOS 
It appears that the metabolic phenotype elicited by insufficient levels of 
eNOS-derived NO relates directly to defects in intermediary metabolism in key 
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peripheral tissues.  Supporting evidence supplied by eNOS KO mice include a 
markedly lower energy expenditure and decreases in mitochondrial content and 
fatty acid oxidation in muscle compared with WT mice 337; and, as expected, 
eNOS KO mice demonstrate an impaired ability to exercise 542. Gain-of-function 
studies show a remarkable ability of eNOS to regulate body composition and 
increase metabolism.  Supplementation of eNOS KO mice with nitrate, which can 
be serially reduced to nitrite and NO, decreases not only blood pressure, but 
visceral fat and TGs as well, thus reversing features of metabolic syndrome 363. 
Furthermore, our studies show that mice overexpressing eNOS acquire an anti-
obesogenic phenotype characterized by resistance to accumulation of white 
adipose tissue in response to a high fat diet, a higher metabolic rate, resistance 
to diet-induced hyperinsulinemia, and remarkably lower plasma levels of FFAs 
and TGs (Chapter III) 286. Our findings were supported by results from an 
investigation of an eNOS phosphomimetic point mutant mouse model that was 
published shortly after our study 543, 544.  Mutation of serine 1176 of eNOS to an 
aspartic acid resulted in increased endothelial NO production as well as 
resistance to diet-induced weight gain and hyperinsulinemia; mutation of the 
residue to an alanine, which cannot be phosphorylated, resulted in insulin 
resistance and features of metabolic syndrome 195, 544. 
How does eNOS regulate metabolism and body composition? Several 
possibilities exist.  Consistent changes in plasma lipids insinuate a central role of 
eNOS in lipid oxidation or synthesis, e.g., eNOS KO mice have elevated plasma 
levels TGs and FFAs compared with WT mice 336, 539, while eNOS transgenic 
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mice show diminished abundance of the lipids 160.  That these differences are 
due to modulation of fat oxidation are suggested by studies showing a direct 
effect of NO on the capacity to oxidize fat.  Not only do eNOS KO mice show 
diminished fat oxidation capacity in skeletal muscle 337, but administration of a 
NOS inhibitor is sufficient to increase serum TGs and diminish hepatic fatty acid 
oxidation in rats 545, potentially by decreasing the activity of carnitine palmitoyl 
transferase 546. Similar, NOS inhibitor-dependent decreases in fat oxidation 
capacity have been found in heart 547. In isolated hepatocytes, treatment with NO 
donors was shown to increase fatty acid oxidation in a cGMP-dependent manner 
by inhibiting acetyl CoA carboxylase (thereby decreasing production of malonyl 
CoA) and stimulating carnitine palmitoyl transferase activity 450.  Interestingly, NO 
also inhibits fatty acid synthesis in hepatocytes 450, which is consistent with 
studies showing that NOS inhibitors 451 or genetic deletion of eNOS increases 
lipid synthesis in liver 452. In skeletal muscle, genetic deletion of eNOS increases 
neolipogenic genes expression while downregulating genes involved in β-
oxidation 337. 
That genes involved in fatty acid oxidation are modulated by NO is 
consistent with data showing that overexpression of eNOS increases the 
expression of peroxisome proliferator activated receptor (PPAR)-α 160, which is 
well known to regulate lipid metabolism 453. However, it is possible that NO 
regulates fat oxidation post-translationally as well. Recent studies show 
widespread S-nitrosation of multiple enzymes involved in intermediary 
metabolism. In particular, the liver enzyme, very long chain acyl-coA 
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dehydrogenase (VLCAD) was shown to be nitrosated at Cys238, which 
increased the catalytic efficiency of the enzyme, and this modification was absent 
in eNOS KO mice 548.  Collectively, these studies suggest that the powerful anti-
obesity effects of eNOS-derived NO could be due to simultaneous increases and 
decreases in fat oxidation and a decrease in fat synthesis.   
 
iNOS promotes insulin resistance  
The iNOS enzyme also regulates systemic metabolism, particularly insulin 
resistance. Although ablation of the iNOS gene has no effect on diet-induced 
obesity, its absence was shown to improve glucose tolerance, normalize insulin 
sensitivity, and prevent derangements in the PI3K/Akt signaling in response to 
insulin 549. Commonly, increases in iNOS expression in skeletal muscle of obese 
mice are associated with increased S-nitrosation of the insulin receptor (IR), IRS-
1, and Akt, suggesting that nitrosative post-translational modifications of proteins 
in the insulin signaling pathway are responsible for iNOS-induced insulin 
resistance 550, 551. The presence of iNOS appears to decrease the abundance of 
IRS-1 by promoting its proteasomal degradation 186. Interestingly, an acute bout 
of exercise was sufficient to downregulate iNOS in high fat-fed rats as well as 
prevent S-nitrosation of proteins involved in insulin 
signaling, and administration of an inhibitor of iNOS (L-N6-(1-iminoethyl)lysine; L-
NIL) pheno-copied these effects 552. Also, aspirin—which is one of the oldest 
known treatments for diabetes 553, 554 and which improves blood glucose and 
insulin sensitivity in diabetic patients 555 and animal models of T2D 556—inhibited 
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iNOS-mediated S-nitrosation of IR, IRS-1, and Akt in skeletal muscle and 
improved insulin sensitivity 557. 
Expression of iNOS in peripheral tissues other than skeletal muscle is also 
important for regulating insulin sensitivity. Selective overexpression of iNOS in 
liver is sufficient to cause hepatic insulin resistance, hyperglycemia and 
hyperinsulinemia 558, and the use of an iNOS-specific inhibitor (L-NIL) reversed 
hyperglycemia, hyperinsulinemia, and insulin resistance in ob/ob mice 188. In 
obesity, proinflammatory macrophages accumulating in adipose tissue are 
responsible for the majority of iNOS expression 189-191 and may propagate the 
inflammatory signaling implicated in insulin resistance 168. Importantly, the role of 
iNOS in adipose tissue appears to differ remarkably from the canonical NO-
cGMP pathway, as high fat diet-induced increases in proinflammatory cytokines 
and macrophage recruitment were attenuated by the administration of sildenafil 
559. Interestingly, lack of iNOS does not prevent age-induced insulin resistance 
560, which suggests that not all insulin resistant states are created equal 561.  In 
agreement with this view it has been shown that mice lacking the nNOS isoform 
are insulin resistant due to a sympathetic, alpha-adrenergic mechanism 562.  
Integration of findings from these studies, and our own, helps to form a 
model illustrating the complex role of NO in regulating obesity and insulin 
resistance (Fig. 43). NO derived from eNOS appears to have both anti-
obesogenic and insulin-sensitizing properties. Its anti-obesogenic role stems 
from its ability to increase fat oxidation in peripheral tissues such as skeletal 
muscle, liver, and adipose tissue. As mentioned above, there is evidence that NO 
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also decreases lipid synthesis in liver. The impact of eNOS on glucose 
metabolism and insulin sensitivity is supported by its capacity to increase the 
transport of insulin and glucose to key peripheral tissues such as skeletal muscle 
and to regulate gluconeogenesis. Additionally, there may be implications for 
eNOS-mediated HISS release, which enhances the vasodilatory properties of 
insulin.  That eNOS prevents hyperinsulinemia in two separate genetic gain-of-
function studies 160, 544 suggests further that it could impact glucose metabolism 
directly by modulating insulin release. Other isoforms of NOS appear to promote 
deleterious changes in metabolism.  In the brain, evidence suggests that nNOS-
derived NO promotes hyperphagia.  The iNOS isoform promotes insulin 
resistance in both liver and skeletal muscle and is critical in inflammatory 
responses in multiple tissues, most notably, the adipose organ. In contrast to 
eNOS, iNOS appears to promote gluconeogenesis, and iNOS has remarkable 
effects on cytokine-mediated insulin secretion. Collectively, it is apparent that NO 
is one of the most critical regulators of metabolism, body composition, and insulin 
sensitivity. Harnessing its beneficial metabolic actions is an exciting prospect for 
combatting metabolic disease in the future. 
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Figure 43. Working model of the systemic effects of NO on obesity and 
metabolism. Illustration of major organs and processes affected by NO and 
nitrogen oxides derived from eNOS, nNOS, and iNOS:  The eNOS isoform 
shows anti-obesogenic and insulin sensitizing effects, which appears to be based 
in the ability of the enzyme to decrease lipid synthesis and promote fat oxidation 
in the liver and skeletal muscle.  Additionally, eNOS may be implicated in the 
secretion of hepatic insulin sensitizing substance (HISS), which might support 
insulin sensitivity in peripheral tissues such as skeletal muscle. eNOS is 
important also for maximizing delivery of insulin and substrates to skeletal 
muscle, and this is likely critical in regulating insulin sensitivity and glucose 
tolerance. Through its actions in liver and pancreas, eNOS may also suppress 
gluconeogenesis and prevent hyperinsulinemia, respectively.  Additionally, NO 
increases the abundance of mitochondria and stimulates substrate oxidation 
capacity in adipose tissue, effectively promoting “browning” of white adipocytes. 
Conversely, other isoforms of NOS appear to have a more malevolent role in 
metabolism.  NO derived from nNOS promotes hyperphagia, and iNOS-derived 
nitrogen oxides can promote insulin resistance and inflammation in key 
peripheral tissues such as liver, skeletal muscle, and adipose tissue.  In addition, 
iNOS may affect glucose homeostasis by increasing glucose output from the liver 
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